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ABSTRACT
DELAYED ANESTHETIC PRECONDITIONING AND
METALLOTHIONEINS-I + II:
NOVEL MEDIATORS OF ANESTHETIC
-INDUCED PROTECTION.

MAY 2009
SCOTT D. EDMANDS, B.A., WHITMAN COLLEGE
M.A., SMITH COLLEGE
Ph. D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Adam C. Hall

Ischemic injury is a common and debilitating outcome of natural illness and as a
complication of commonly performed medical procedures. Whereas naturally occurring
ischemic insults are often the result of unpredictable events, such as in the case of stroke
or heart attack, the risk of operative and perioperative ischemia is somewhat better
characterized in the clinical setting. Given the prevalence and severity of outcomes in
ischemic injury, there is significant interest in developing better pharmacological and
procedural approaches to improve patient outcomes. One approach that has shown
significant promise in the laboratory setting, particularly in the context of planned
medical procedures, is the use of delayed anesthetic preconditioning. Delayed anesthetic
preconditioning is a phenomenon whereby a prior exposure to clinical concentrations of
commonly used inhaled anesthetics, including isoflurane, induces the production of
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endogenous protective proteins that are able to provide robust protection against
subsequent, potentially toxic, ischemic insults. Although many aspects of delayed
anesthetic preconditioning have been previously described, a complete understanding of
preconditioning mechanism has yet to emerge.
The studies described in this dissertation aim to further our understanding of
molecular mechanisms involved in delayed anesthetic preconditioning. In the first
project, I used DNA microarray to identify genes that were differentially expressed in
adult rat liver, kidney and heart following a clinically relevant exposure to the inhaled
anesthetic isoflurane. By selecting those genes that were differentially expressed in
multiple tissues, I was able to identify a small group of interesting genes for further
study. In my second study, I chose from our list two related genes, metallothioneins I +
II, to analyze for a role in anesthetic-mediated protection. Using a combination of
approaches, I was able to establish that metallotioneins I + II play an essential role in
delayed anesthetic preconditioning. In the final study of this dissertation I explore a
possible role for metallothioneins I + II as sensor molecules, involved in detecting
cellular oxidative stress.
Taken together, these three studies represent an important contribution to our
understanding of the mechanisms of delayed anesthetic preconditioning and how they
might contribute to protecting against ischemic stroke.
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CHAPTER 1
INTRODUCTION

Ischemia Reperfusion injury (IRI) is a common complication in both surgical and
trauma patients that leads to high degree of morbidity and mortality in a wide range of
organ systems including lung 1, heart 2, brain3, liver 4, kidney 4, and intestine 5. In
neurological tissue, ischemia-producing complications from neurosurgical, vascular and
cardiac procedures can induce stroke, seizures, and neuropsychological deficits 3.
Despite advances in our understanding of what causes it, ischemic stroke remains a
serious complication of surgery. For example, following coronary artery bypass grafting,
recent studies show an incidence of stroke ranging from 1.6-5.2%, while coratid
endarterectomy (CEA) carries a risk of 0.25% to 7% 3. In the North American CEA trial,
35% of stokes occurred during the procedure while the remainder occurred after the
patient left the operating room. Of these, just over half of the delayed events occurred
within 24 hours of surgery 3. Given this substantial rate of surgical complication, there is
significant clinical interest in developing both procedures and pharmacological agents
that are capable of either protecting or preconditioning tissues against the risk of
ischemia-reperfusion induced injury. One approach that has been gaining significant
interest for its potential to protect against ischemic injury in a number of tissues is the
phenomenon of delayed anesthetic preconditioning (APC) 3,6. In delayed anesthetic
preconditioning, a clinical dose of an inhaled anesthetic is sufficient to set in motion an
array of endogenous cellular pathways that are able to defend tissues against potentially
toxic ischemia for days following the initial preconditioning treatment 3. However,
1

before detailing anesthetic preconditioning and possible mechanisms of protection, it’s
useful to have a basic overview of ischemic damage and the pathways that are involved
in order to better understand preconditioning.

Biology of Ischemia-Reperfusion injury
Although ischemic injury can occur in any tissue, this introduction focuses on
ischemic injury in the brain, or ischemic stroke. Ischemic stroke is the result of a
temporary or permanent reduction in cerebral blood flow due to blockage of a major
cerebral artery from thrombosis (originating locally) or embolism (originating
elsewhere). Reduced blood flow and concomitant reduction in glucose and oxygen
delivery sets in motion a complex cascade of molecular and cellular events, which, if
untreated, ultimately leads to cellular death 7. In animal models of ischemic injury, such
as middle cerebral artery occlusion (MCAO), and in human stroke, the ischemic lesion
can typically be divided into two distinct regions (See Figure 1.1). The core of the
ischemic lesion is made up of the tissue immediately served by the occluded artery and
receives blood flow that is 25% or less of normal flow7. Radiating out from the core is a
region called the penumbra that, while not neurologically functional, maintains structure
as it receives collateral perfusion (< 40% normal) from nearby blood vessels7. If blood
flow is not restored within a few hours, evidence indicates that tissue in the penumbral
region will ultimately die and become part of the core. 7,8. Injury and death pathways in
the core and penumbra differ markedly 9. In ischemic the core, due to a near complete
lack of available energy, cell death proceeds primarily by necrosis while in the penumbra,
cells die by a mixture of necrosis and apoptosis with apoptosis becoming more common
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the greater the distance from the core 10. In the context of neuroprotection, there appears
to be little that can be done to protect against the near complete failure of energy systems
in the core, however, there is evidence that targeting the penumbra for protective
treatments could have significant long-term benefits for improving patient outcomes10.
Figure 1.2 shows a simplified overview of the molecular and cellular events
involved in the ischemic cascade. It is important to note that while the figure depicts a
stepwise progression of ischemic injury, in reality many of the depicted events will
overlap one another both spatially and temporally10. Lacking energy stores of its own,
the brain depends on a steady supply of oxygen and glucose to undergo mitochondrial
oxidative-phosphorylation for the production of ATP. Therefore, attenuation of blood
flow leads to rapid depletion of energy substrates for mitochondrially produced ATP,
particularly oxygen and glucose, triggering a conversion to anaerobic glycolysis.
Anaerobic glycolysis, with a resultant increase in cellular lactate, promotes increased
reactive oxygen species (ROS) production and inhibition of cellular protein synthesis that
may contribute to ischemic injury10. Despite the energetic switch to anaerobic
metabolism, ATP levels fall rapidly in the core of the ischemic lesion11. Decreased ATP
levels cause ionic gradients normally maintained by Na+/K+- ATPases and Ca2+/H+ATPase pumps to dissipate, leading to neuronal and glial depolarization 12,13. This
situation is further compounded by the reversal of Na+/Ca2+ transporters 14.
Depolarization of neuronal and glial membranes triggers voltage dependent calcium
channels to open, facilitating an influx of extracellular calcium which, in turn, leads to
the release of excitatory neurotransmitters, including glutamate.13. Accumulation of
extracellular glutamate causes the ionotropic receptors N-methyl-D-aspartic acid
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(NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA), to open channels for Na+/Ca2+ and Na+ respectively, compounding
calcium overload and promoting cellular edema respectively12. Furthermore,
release of Ca2+ via an IP3 –dependent pathway through activation of metabotropic
glutamate receptors from organelles including endoplasmic reticulum,
mitochondria, synaptic vesicles and Ca2+ binding proteins may further increase
intracellular Ca2+ levels10.
Increased intracellular Ca2+ plays an important role in cerebral ischemic
injury by triggering the activation of an array of Ca2+ -dependent enzymes
including protein kinase C, phospholipase A2, phospholipase C, cyclooxygenase,
calcium-dependent nitric oxide synthase, calpain, proteases and endonucleases10.
These events in turn result in the production of cytotoxic products including ROS,
reactive nitrogen species (RNS) and leukotrienes which, as discussed below, play
an important role in ischemic damage10.
ROS are generated by multiple pathways involved in the ischemic cascade
and, in turn, contribute significantly to ischemic injury. ROS are produced by
inhibition of the oxidative phosphorylation machinery due to ionic imbalances in
the mitochondria, as part of enzymatic processes such as the cyclooxygenasedependent conversion of arachidonic acid to prostanoids, by the degradation of
hypoxanthine and by increased cellular lactate10. Furthermore, inflammation can
significantly elevate local ROS and RNS levels15. ROS react with and oxidize cellular

lipids, proteins, and DNA, leading to dysregulation of cellular processes,
4

perturbations to ion homeostasis and interruption of normal cell signaling12,15,16.
Ultimately, if ROS damage accumulates, it will eventually trigger cellular apoptosis 17.
At the brain structure level, damage to cellular membranes by ROS contributes to the
breakdown of the blood/brain barrier and promotes cerebral edema 16.

Rapid Ca2+ influx along with increased ROS levels rapidly induces the
upregulation and activation of a number of pro-inflammatory transcription factors
including NF-Kappa B, hypoxia inducible factor 1 (HIF-1) and STAT313.
Activation of these factors, leads to increased production of inflammatory
cytokines including TNF-alpha and IL-1beta, and inflammation related enzymes
including iNOS and COX-213. Ischemia also leads to increased expression of
vascular adhesion molecules such as ICAM-1 and selectins in local vascular
tissue, thereby increasing numbers of neutrophils, macrophages, and monocytes at
the site of injury within hours of the original insult. The pathogenic role of
immune cells at the site of injury is a subject of debate10. Macrophages and
microglia may be beneficial through their roles in tissue remodeling. However,
activated phagocytes produce large quantities of ROS and RNS that may further
increase the oxidative stress of the tissue and contribute cellular damage12,13,16. The
rate and severity of cellular damage are dependent on the degree of blood flow
attenuation. In the core, where blood flow in the lowest, these events occur rapidly,
however in the penumbra the progression of ischemic injury will play out over the course
of days 13.

5

Depending on the severity of the initial ischemic insult, restoration of blood
supply alone may not be sufficient to rescue affected tissues from injury 18. Indeed,
disruption of normal energy pathways due to dysregulated pathways, ionic imbalances
and cellular damage, the return of higher glucose and oxygen levels can lead to large
increases in toxic ROS stemming both from inefficient mitochondrial oxidative
phosphorylation 19 and from the energetic switch to the ROS producing NADPH oxidase
pathway 18. These increases in ROS upon reperfusion lead to further oxidation of cellular
proteins, lipids and DNA that can, in turn, trigger cellular apoptotic and necrotic
pathways13. The complexity and number of pathways involved in the cellular response to
ischemia makes treatment extremely challenging10. In the context of neuroprotective
treatments, such as delayed anesthetic preconditioning, the aim is to control the degree of
these potentially toxic pathways such that cells are ultimately able to return to normal
metabolism following the reinstatement of a normal blood supply.

Treatment of ischemic stroke
Experimental animal models of focal ischemia have been developed in recent
decades and have provided the basis for most of our understanding of the mechanisms
involved in cerebral ischemia. From these models, two main approaches have emerged
for the treatment of ischemic stroke: recanalization and neuroprotection 10.
Recanalization involves the clearing of the arterial blockage by either surgical or
pharmacologic means. Mechanical recanalization, using a mechanical embolectomy
device to clear the blockage has shown positive early results, but is not yet widely used
for treatment 20. Currently the recombinant tissue-type plasminogen activator (rt-PA) is
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the only approved pharmacological treatment for acute ischemic stroke when
administered within three hours after the onset of symptoms21. While somewhat
effective, only a small number (1-8.5%) of hospitalized patients receive rt-PA treatment
due to the short window for treatment, the necessity for computed tomography scan and
other exclusions 10,22.
Neuroprotection, on the other hand, complements recanalization with the
aim of protecting the penumbral tissue and preventing growth of the ischemic core until
normal blood flow can be restored10. This approach arises from evidence, noted above,
that reperfusion alone is not sufficient to prevent the progression of the ischemic lesion10.
Numerous potentially neuroprotective agents that include glutamate release inhibitors,
NMDA and AMPA antagonists, free radical scavengers, calcium channel blockers and
chelators, and NO antagonists, have been directed at the various harmful steps of the
ischemic cascade with the intent of preventing or delaying damage until homeostasis can
be restored10. However, though many substances have shown promise in vitro studies or
in animal models of experimental stroke, the majority of agents have failed in clinical
models. Reasons for this are unclear and are likely due to multiple variables including
experimental design, small sample sizes and heterogeneity of the clinical population10. It
may be too, that the treatment of any one pathway may be insufficient to for cellular
protection, especially when so many pathways are affected through the ischemic cascade.
In support of this, recent preclinical data suggest that approaches utilizing multi-drug
combinations might have greater clinical effectiveness than those targeting individual
agents 23. Given the overall lack of effective measures against ischemic damage, delayed
preconditioning has arisen as a potentially useful therapeutic intervention. A central
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benefit of the preconditioning approach is that preconditioning, by its nature, induces
endogenous proteins that address multiple important points in the ischemic cascade (See
mechanism section below). By improving our understanding of preconditioning
mechanisms, there is promise that therapies that are able to harness the power of these
pathways will lead to improved patient outcomes.

Introduction to general anesthetic agents
General anesthetics comprise a wide range of structurally diverse molecules that
are broadly categorized as volatile anesthetics, anesthetic gases, alcohols and intravenous
agents (see Figure 1.3 for structures of these agents). Most general anesthetics will
effectively produce unconsciousness/hypnosis, immobility, and amnesia along with
varying degrees of analgesia, muscle relaxation and depression of autonomic reflexes 24.
Because general anesthetics vary in their ability to confer all of these functions, modern
anesthesia typically supplements general anesthetics with analgesics and neuromuscular
blockers 24. General anesthetic agents are thought to exert their anesthetic properties
largely through positive or negative allosteric modulation of agonist activity at pre- and
post-synaptic ligand-gated ion channels, though voltage-gated ion channels and g-protein
coupled receptors may also play a role24. In simpler form, anesthetics induce
unconsciousness by blocking the propagation of neuronal action potentials either by
inhibiting pre-synaptic excitatory transmitter release or by strengthening post-synaptic
inhibitory response and thus blocking the excitation of the post-synaptic neuron. While
all classes of general anesthetics are considered to be effective at inducing anesthesia,
currently only volatile anesthetics, especially the halogenated ethers including isoflurane,
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halothane, sevoflurane and desflurane, are thought to induce delayed anesthetic
preconditioning. 19,25. The mechanisms by which these anesthetics induce delayed
preconditioning are likely distinct from those by which they induce unconsciousness and
will be discussed below 26,27.

Background of Preconditioning
Preconditioning is an important biological phenomenon where exposure to a sublethal stressor including heat stress, exercise, global or focal ischemia, inflammation, or
exposure to an inhaled general anesthetic 28,29, can induce endogenous pathways that are
able to protect against a subsequent, more severe ischemic insult 19. Preconditioning
typically manifests in at least two distinct temporal windows. Early protection, also
called “classical preconditioning” begins almost immediately following the
preconditioning stimulus and dissipates after 1-2 hours 30. In this type of
preconditioning, protection is derived primarily from post-translational modifications to
existing proteins 31. Many of the pathways in classical preconditioning appear to
converge on mitochondrial targets and include activation of phosphoinositide-3-kinase,
protein kinase C, endothelial nitric oxide synthase, glycogen synthase kinase 3beta, and
p38 mitogen-activated protein kinases. Activation of these signaling molecules leads to
changes to key mitochondrial proteins resulting in altered metabolism and reduction in
cellular death31. By contrast, delayed preconditioning appears to rely on de novo protein
synthesis in order for protection to emerge. As a result, protection begins later, 12-24 hrs
following the preconditioning stimulus, and can provide protection lasting several days3234

. The remainder of this dissertation will concern itself with delayed preconditioning.

9

The idea that endogenous pathways could be harnessed in order to protect against
hypoxia and ischemia dates back more than six decades. Noble, in 1943, first proposed
that brief bouts of global ischemia might protect the entire organism and improve brain
function during more extreme hypoxia 19. Janoff in 1964, examining changes to rabbit
lysomal proteins following shock, coined the term “preconditioning” to denote sublethal
stimulation that leads to later protection 35. Two decades later, in the first reported
clinical test of classical, or early ischemic preconditioning (IPC), Murry, in 1986,
reported that brief, non-injuring bouts of ischemia protected canine heart against more
protracted, potentially lethal ischemia 30. Finally, in the first report of delayed IPC,
Kitagawa in 1990, demonstrated that short periods of global ischemia in gerbil were
protective against more potent ischemia 1-2 days following the preconditioning regimen
36

.
While these early reports of preconditioning all used ischemia as the

preconditioning agent, Kersten et al., in 1997, demonstrated anesthetic-induced classical
preconditioning against ischemia-reperfusion injury in canine heart using the inhaled
anesthetic isoflurane 29. Only very recently, in 2004, did Tanaka demonstrate that an
inhaled anesthetic (again isoflurane) could induce delayed protection against the acute
effects of ischemia in rabbit heart in a manner similar to that reported in regards to
delayed ischemic preconditioning 37. The work of Kersten and Tanaka has been
supported and expanded upon by numerous studies in both animal models and through
clinical studies 6,31,38. Although numerous studies showed anesthetic-induced protection
against the acute effects of ischemia, ie. the tissue damage immediately following the
ischemic insult, there remained questions as to the long-term benefits of delayed
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preconditioning both in terms of tissue health and in terms of functional outcomes 6. This
question was recently addressed in a study where rats preconditioned with isoflurane and
subjected to middle cerebral artery occlusion showed better histological and neurological
outcomes at one month compared to non-preconditioned controls 39, thereby confirming
that delayed preconditioning can improve long-term as well as acute outcomes in an
animal model.
Since Tanaka’s first report of isoflurane-induced delayed preconditioning in
rabbit cardiac tissue, inhaled anesthetics have also been shown to induce endogenous
protection in a range of other tissues including brain 40, spinal cord 41, liver 42, skeletal
muscle

43

, and immune cells 44. In addition to supporting the hypotheis that inhaled

anesthetics can induce protection, these studies support Noble’s 1943 hypothesis that
anesthetic preconditioning (although he envisioned hypoxia as the preconditioning agent)
might be able protect the whole of the organism against ischemic injury. Taking an even
broader view, a very interesting characteristic of delayed anesthetic preconditioning is
that it appears to be conserved in a wide range of organisms including rabbit33, rat40,
mouse45, gerbil36, and human44. Isoflurane has even recently been reported to effectively
precondition the invertebrate Caenorhabditis elegans (C. elegans) against hypoxic injury,
suggesting a fundamentally conserved cellular response to certain types of stress-- a
property that we exploited to the inform data analysis in our first study (See Chapter 2;
Methods)46.
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Current understanding of mechanisms involved in delayed anesthetic
preconditioning.
The mechanisms by which inhaled anesthetics induce anesthesia are likely distinct
from those that induce preconditioning. Although the mechanisms of anesthetic
induction of preconditioning are far from clear, they almost certainly rely on a transient
increase in reactive oxygen and nitrogen species 47. Recent studies suggest that inhaled
anesthetics may initiate APC through ROS production by inhibiting the mitochondrial
electron transport chain at complex I, III or V26,27,48, leading to an increase in cellular
levels of ROS including the oxygen radical, superoxide (.O2)26,49. The RNS nitric oxide,
produced by endothelial nitric oxide synthase and/or inducible nitric oxide synthase, is
also widely reported to be involved in the induction of delayed anesthetic preconditioning
47,50

. Though the specifics are lacking, ROS and RNS are thought to act as signaling

molecules that trigger the production of other proteins involved in cellular protection, eg.,
superoxide dismutase, catalase, and hexokinase-2, 19,47.
As described above, ischemic injury proceeds via a complex pathway involving a
number of molecular players and pathways. Interestingly, in addition to NO and .O2
described above, many of these molecular players and pathways involved in the ischemic
cascade are the same as those described in relation to delayed anesthetic preconditioning
(Figure 1.4) 19. These include: transcription factors (STAT3 51, NFKB 50), inflammatory
mediators (COX-2 37, iNOS, 50, eNOS 52), Antioxidants (Mn-SOD 53), ion channels, and
other cellular enzymes (12-lypoxygenase 54,) Kinases (P13Kinase 55), mediators of
apoptosis (Apaf1 46), and mitochondrial K(ATP) channel proteins (Vdac 56, and K+-ATP
channels 57,58). Although some of the details of delayed preconditioning have been
12

described, our understanding of how these molecules interact with one another to confer
protection is as yet incomplete. A better understanding of the molecular players and the
interactions that they have with one another will be essential for us to understand how
anesthetic-induced protective measures work and how they might be better utilized for
clinical protection against ischemia.
Finally IPC and APC appear to protect via similar mechanisms. Indeed a recent
survey of mechanisms involved in delayed preconditioning suggest that there is
significant similarity, if not identity in the pathways ascribed to preconditioning,
regardless of the source of preconditioning stimulus19. Though both APC and IPC have
been shown to protect in the clinical setting, APC has been gaining interest due to the
ease with which it can be administered and to the increased safety of APC over IPC 59, 60
2

. For this reason, we chose to focus our efforts on the mechanisms of delayed anesthetic

preconditioning.
In the chapters that follow, we describe three studies aimed at furthering our
understanding of the phenomena of delayed anesthetic preconditioning. In Chapter 1, we
describe the use of DNA microarray to identify previously unidentified anestheticregulated genes with the potential for involvement in anesthetic preconditioning. In the
second chapter, we selected metallothioneins I + II, two of the genes identified in Chapter
1, and assessed their involvement in delayed anesthetic preconditioning. Finally, in
Chapter 3, we examine how metallothioneins I + II fit in to what is already known about
the mechanism of delayed preconditioning. Specifically, we ask if metallothioneins
might act as sensors/transducers of oxidative stress during preconditioning. Taken
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together, these three studies represent an important contribution to our understanding of
the mechanisms of delayed anesthetic preconditioning.
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Figure 1.1. Cartoon of ischemic lesion. The core of the ischemic lesion (light grey) is
made up of the area immediately served by the occluded artery and is comprised of dead
or dying cells. Radiating out from the core is the penumbra which is served by collateral
blood flow from nearby blood vessels. Penumbral tissue, because of it’s potential to
survive if blood flow is restored, is the target of neuroprotective approaches to ischemic
injury. Figure adapted from: Acute Ischemic Stroke: New Concepts of Care ©
1998-1999 Genentech Inc.
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Figure 1.2. The ischemic cascade. A.) Normal cell: With no blockages, energy
substrates oxygen and glucose are delivered in the amounts needed for normal cellular
function. This allows ATP requirements to be met and energy requiring processes such
as maintenance of ion gradients continue normally. B.) Shortly following arterial
occlusion, glucose and oxygen levels drop, leading to rapidly diminished ATP levels.
Low ATP levels causes the failure of Na+/K+-ATPases and the dissipation of membrane
potential. C.) Drop in membrane potential triggers the opening of voltage dependent
Ca2+ channels leading to massive influx of extracellular Ca2+. This in turn causes
glutamate to be exported where it accumulates in the extracellular space. There it
interacts with NMDA and AMPA to promote the entry of even more Ca2+ and Na+ into
the cell. Increased Ca2+ can inhibit mitochondrial respiration further, leading to increased
ROS. Ca2+ will also activates a variety of cellular enzymes that can lead to cellular
damage. Finally, Ca2+ along with increased ROS and RNS activate transcription factors
that code for greater numbers of the enzymes already described as well as inflammatory
cytokines and the upregulation of vascular adhesion molecules that will facilitate the
arrival of activated phagocytes to the site of the injury. D.) Within hours of the initial
injury, activated phagocytes and microglia arrive to the site of injury where they produce
large quantities of reactive oxygen and nitrogen species. They may also play a protective
role by assisting in tissue remodeling and repair. 10,11,13
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Figure 1.3. Chemical structures of selected general anesthetics. In the context of
delayed preconditioning, the halogenated ethers including halothane, enflurane,
sevoflurane and isoflurane have thus far proven most effective. From Krasowski and
Harrison 1999 24.
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Figure 1.4. Reported molecular players in delayed anesthetic preconditioning.
Previously reported molecular participants are overlayed on figure of the ischemic
cascade. Red stars indicate molecules or pathways that have been reported to be involved
both in ischemic injury and in preconditioning-mediated protection from ischemia.
Anesthetic preconditioning has been reported to be mediated by: 1.) Modulation of
mitochondrial K+-ATP channels 58. 2.) Scavenging of ROS 47,61. 3.) Regulation through
STAT351. 4.) Induction of NF-kappa B50,62. 5.) Induction of HIF-163 6.) Increases in
COX-2 activity37. 7.) Modulation of phospholipases 64. 8.) Increases in production of
nitric oxide by endothelial and/or inducible NOS 50,52. 9.) Modulation of TNF-alpha and
IL-1beta levels65. 10.) Modulation of ICAM-1 and selectins expression 66 and 11.)
Modulation of inflammation 67
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CHAPTER 2
IDENTIFICATION OF GENES DIFFERENTIALLY
REGULATED IN RAT LIVER KIDNEY AND HEART FOLLOWING
ISOFLURANE EXPOSURE

Introduction
For our initial study, we employed DNA microarray to identify novel anestheticregulated genes following a clinical exposure to the inhalational anesthetic agent,
isoflurane. As a focus for our search we considered recently reported observations of
ischemic injury and of anesthetic preconditioning to inform our experimental design and
our data analysis. Firstly, ischemic injury proceeds via a complex cascade of molecular
events involving a number of ontological pathways such as the disruption of energy
pathways, modulation of cell death pathways, dissipation of ion gradients and
enhancement inflammatory processes 11. Furthermore, studies have shown that genes
involved in delayed APC target a number of different ischemia-related pathways
(including iNOS 40, MT I + II 45, COX-2 37, and mitochondrial/sarcolemmal K+/ATP
channels58). Many studies have considered individual molecular and cellular pathways
involved in protection against ischemia, however given the complexity of ischemic
injury, we hypothesize that there are additional protective elements yet to be revealed.
Furthermore, we noted that the protection provided by anesthetic preconditioning
is a widely reported phenomenon and has been described in multiple organisms (mouse45,
rat40, rabbit37, and human 38) and tissues (heart37, brain40, skeletal muscle 43, kidney
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68

spinal chord41). The concept that preconditioning may be a basic response to

environmental stress is supported by a recent study by Jia and Crowder, describing
isoflurane and halothane preconditioning in C. elegans2,46. Thus, we hypothesized

that by selecting genes differentially regulated in multiple tissues, we might
identify genes involved in a general mechanism for preconditioning.

Methods
Animal Care
Male Spraque-Dawley rats were acquired from Jackson Laboratories (250 and
300 grams; Bar Harbor, ME) and allowed to acclimatize for two weeks prior to
experiments. Animals were maintained under a standard 12/12 light/dark cycle at room
temperature and given access to food and water ad libitum. Animals were housed and all
experiments carried out with protocols approved by Smith College Institutional Animal
Care and Use Committee (Northampton, MA, USA) according to the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health, 1996).

Arrays
Rat specific DNA microarrays were obtained from the Rutgers Neuronal Gene
expression Lab (NGEL; Piscataway, NJ). Briefly, each array was constructed from a
collection of 4967 probes representing approximately 4900 genes printed onto a poly-Llysine slide. Probes were 65-70 nucleotides in length and were designed to optimize
melting temperature and to minimize homology between probes. Further information
about these arrays can be found at the web site http://www.ngelab.org.
20

Isoflurane Exposure and Tissue Collection
Animals receiving isoflurane treatment were placed in an induction chamber and
induced with 3% isoflurane/97% medical grade air (vol/vol) until loss of righting reflex
(2-3 minutes). Anesthesia was then maintained at 2% isoflurane/98% air ~1.5 MAC
(minimum alveolar concentration) for the remainder of the 90 minute exposure period.
Body temperature was maintained at 37˚C throughout the treatment using heated gel
packs and oxygen levels were monitored using a model V3304 pulse oximeter (Surgivet;
Waukesha, WI). Animals were observed to maintain > 95% oxygen saturation at all
times. Upon completion of the anesthetic exposure, test animals were immediately
sacrificed by decapitation. Samples from liver, kidney cortex and heart ventricle were
collected and homogenized with a Polytron homogenizer (Brinkmann; Westbury, NY) in
ice cold Trizol (Invitrogen; Carlsbad, CA). Because stress has been demonstrated to
influence gene expression 69, control animals were maintained in their cages until the
time of sacrifice. Each control animal was handled gently and then rapidly decapitated.
Tissue was processed in the same manner as test animals. Tissue/Trizol homogenates
were stored at –20˚C until further processing. All animals were sacrificed during the
same daily 5hr window in order to diminish confounding factors from diurnal variations
in gene expression 70.

RNA Preparation
Total RNA was isolated from Trizol/tissue homogenate by adding chloroform and
performing a phase extraction. The aqueous phase was mixed with ethanol 1:3 v/v and
added to an Rneasy column (Qiagen: Valencia, CA). Manufacturer instructions were
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followed for column washing and elution of RNA. Purified RNA was quantified using a
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies; Rockland, DE). All
samples yielded A260/A280 ratios between 1.9 and 2.1. Isolated RNA was stored at –80˚C
until further use. The same RNA preparations were used for both microarray
experiments and subsequent QRT-PCR verification of selected genes.

Experimental Design
For each tissue, RNA from an isoflurane-treated animal was competitively
hybridized against control RNA from a pool comprised of equal amounts of RNA from 8
control individuals 71. For each tissue, this experiment was performed twice using the
same labeling schema, and a third time reversing the labeling schema as a dye-flip
control to ensure no dye-specific artifacts. These three experiments were repeated for
each of 3 experimental animals, for a total of 9 arrays per tissue.

Target Labeling and Hybridization
Microarray targets were prepared using the Genisphere 350 dendrimer labeling
system according to manufacturer instructions (Genisphere, Inc.; Hatfield, PA) 72.
Briefly, 2.5µg of isoflurane-treated and pooled control RNA were reverse-transcribed to
cDNA in separate tubes using Superscript II (Invitrogen), and oligo d(T)18 primers
containing unique, label-specific capture sequences. Samples were then alkaline
hydrolyzed to destroy residual RNA. Control and test tagged cDNAs were mixed,
applied to arrays and sealed in watertight chambers (GeneMachines; Ann Arbor, MI), and
allowed to hybridize for 48-72 hrs in a waterbath at 55˚C. Arrays were washed one time
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for 10 min (2X SSC, 55˚C), followed by two washes for 10 min (0.2X SSC, room
temperature). Arrays were then spin dried prior to labeling. Hybridized arrays were
labeled with fluorescent-labeled dendrimer and incubated 2 hrs at 61˚C. Labeled arrays
were washed and dried as described above and scanned using an Axon GenePix 4100
scanner and GenePix 4.0 software (Axon Instruments; Union City, CA).

Data Analysis
Scanned array images were processed using Genepix 4.0 (Axon Instruments).
Spots were eliminated if the signal to noise ratio of the spot fell below 2.0. Statistical
analysis of each tissue group was performed using G-Processor (version 3.1, Zhong Guan
(http://bioinformatics.med.yale.edu). This package performs a Lowess normalization
71

and yields a differential expression ratio along with a Student’s t-test p-value for each

probe. For each tissue, the gene list was screened for statistical significance in Excel
(version 11.5.3 for MacIntosh ; Microsoft, Redmond, WA) using the following criteria:
for each gene selected, p-value ≤ 0.05, spot data were valid for ≥ 7 of the 9 arrays and
level of differential expression was ≥ 1.2 compared to control. The final list of
“interesting genes” was compiled by choosing genes that were differentially expressed in
more than one tissue and whose expression pattern (up or down) was consistent in the
different tissues.
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QRT-PCR
In order to verify results from our microarray, three of the highly regulated genes
from the liver array were selected for verification by quantitative reverse-transcriptase
polymerase chain reaction (QRT-PCR). See Table 1 for primer and probe sequences. All
primer/probe sets were acquired from Integrated DNA technologies (IDT Inc., Coralville,
IA). Each QRT-PCR reaction was carried out in a single tube on an Applied Biosystems
7700 “Taqman” instrument (Applied Biosystems; Foster City, CA). The QRT-PCR
reaction mix was comprised of 1X PCR buffer (Invitrogen, Carlsbad, CA), 6mM MgCl2,
0.67 mM each dinucleotide, 6.75 pmols each of forward and reverse primers, 100 nM
FAM/TAMRA probe, 1.5 units Superase-in (Ambion; Austin, TX), 15 units Superscript
II (Invitrogen), 0.75 units Platininum Taq Polymerase (Invitrogen) to a final volume of
15µl. Each reaction was run one cycle of 30’ at 42˚, 1 cycle of 3’ at 95˚ and 40 cycles of
1’ at 60˚ and 20” at 95˚. Universal mouse RNA (Stratagene, La Jolla CA) was used to
create a standard curve for each gene of interest and for the normalization gene. Gene
reactions were run in triplicate, averaged and normalized to rat protein tyrosine
phosphatase, receptor type C, a gene that was chosen because it showed no differential
regulation on any of the tissue arrays.

Results
Based on our selection criteria, all of the tissues tested showed differential gene
expression in response to a 90 min dose of 2.0% isoflurane. Liver showed the greatest
number of differentially regulated genes in response to isoflurane treatment with 725 of
4900 (~15% ) genes showing either up or down differential regulation ≥ than 1.2 fold as
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compared to the pooled control. Kidney had fewer with 214 (~4%) differentially
regulated genes and heart had the least with 137 (~3%). The full list of differentially
regulated genes for each tissue is available in Supplementary Tables 1-3.
Of the genes described above, 34 of the 4937 genes on the arrays were
differentially regulated in the same direction in at least 2 tissues (see Table 2 for gene
descriptions). Of these, 19 were up-regulated and 15 were down-regulated. Figure 2.1
shows a Venn diagram of the distribution of the 34 co-regulated genes. From the genes
described in Table 2, a number of broad ontologies were represented including:
apoptosis, necrosis and survival signaling, regulation of energetic pathways, modulation
of cellular redox, maintenance of cellular ion gradients, regulation of inflammatory
response, and regulation of vesicular transport.
We selected 3 of the genes that were significantly regulated on the liver arrays
and assessed their expression levels by QRT-PCR using the same RNA as in the array
experiments. As shown in Figure 2.2, there was good agreement between microarray and
QRT-PCR differential expression levels, suggesting that array values reflect a reasonable
approximation of differential expression levels under the conditions we used.

Discussion
Ischemic injury plays a central role in the pathology of a range of human illnesses
from stroke and cardiac arrest to tissue transplant or complications from childbirth. In
the clinical setting the risk of perioperative stroke following surgical procedures present a
small but significant risk 59. In situations where there is a known risk of ischemic
damage, such as during and after certain surgical procedures or organ transplant, one
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treatment option that has shown promise for improved clinical outcomes is the use of
delayed anesthetic preconditioning. While an intense focus on anesthetic preconditioning
has illuminated a number of the mechanisms involved in providing protection, a complete
picture has yet to develop. We therefore employed a unique approach to identify novel
genes that may be involved in common pathways of anesthetic preconditioning. In the
current study, we used a novel approach to analyze microarray data from three rat tissues
that prioritized genes differentially regulated in more than a single tissue. While this
approach might prove less effective for the identification of tissue or process-specific
pathways, it enabled us to focus on genes potentially involved in common pathways.
Using these parameters, we identified 34 genes that were differentially regulated in
multiple tissues following a clinical exposure to the volatile anesthetic isoflurane.
Literature investigations of the genes contained on our list revealed a number of potential
targets for further investigation in the context of anesthetic preconditioning.
Seven of the genes we identified (Vdac2, BAD, Pld1, Slc25a3, Atp1a1, MT-I,
MT-II ) are broadly involved in apoptosis, necrosis and survival signaling. Voltage
dependent anion channel-2 (Vdac2) is a mitochondrial outer membrane protein. It is a
component of the mitochondrial permeability transition pore that participates in
transportation of metabolites and helps regulate cellular progression towards apoptosis73.
It is involved in the global regulation of mitochondria under stress, and has been
implicated in the regulation of both apoptotic and necrotic pathways74, both of which are
involved in ischemic injury. Vdac2 has also been suggested to participate in APC 31.
Vdac2 activity is regulated, at least in part, by another in our gene list, bcl-2 associated
death agonist (BAD) 73. BAD has been found to be modulated during early ischemic and
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anesthetic preconditioning 75 76, although to our knowledge, differential regulation of
BAD has not been associated with anesthetic treatment (others have found BAD to be
down-regulated in response to oxidative stress77).
Phospholipase D1, is a pleotropic protein whose cleavage by caspases has been
reported to promote apoptosis via a p53-dependent pathway 78. Its activity during
ischemia-reperfusion has also been tied to signaling for necrotic death 64. Solute carrier
family 25, member 3 (Slc25a3) is another pleotropic protein and has been reported to be a
regulator of mitochondrial cytochrome-c release (a protein important for caspasedependent apoptosis) 79. ATPase, Na+/K+ transporting alpha 1 polypeptide (Atpa1) is the
catalytic subunit of a membrane bound Na+/K+ transporter ATPase. The n-terminus of
this subunit has recently been shown to interact with inositol 1, 4, 5 triphosphate receptor
to trigger Ca2+-mediated survival signaling80,81. MT I + II have been shown to be
protective against apoptotic and necrotic death in a number of tissues82-84. This protection
may arise from roles in reducing oxidative stress and by triggering survival pathways that
can protect against apoptosis and necrosis82-85.
Disruption of Ca2+ , Na+, and K+ ion gradients is an important step in the
progression of ischemia-reperfusion injury 11. Two of the genes described above (Pld1
and Atpa1) have described roles in the regulation of cellular Ca2+ and Na+/K+, ion
gradients respectively 64,80. Pld1 is a membrane protein that catalyzes the hydrolysis of
phosphatidyl choline to for phosphatidic acid. It has been shown to interact with protein
kinase C (PKC) and extracellular responsive kinase (ERK) and is involved in
sarcolemmal Ca2+ control in heart and skeletal muscle 64. Atpa1 is an integral membrane
protein that is involved in establishing and maintaining Na+ and K+ gradients across the
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plasma membrane and therefore its regulation may play a role in maintaining ionic
balance in ischemic tissue81.
Inflammatory response plays a significant role in later stages of ischemic injury and
can greatly influence survival of penumbral tissue. Four of the genes we identified,
interferon regulatory factor 1 (Irf1), basigin (bsg) and metallothioneins I + II have been
reported to participate in inflammatory response86,87. Irf1 regulates the transcription of the
inflammatory cytokines interferons alpha and beta and acts as a transcriptional regulator
of genes controlled by these proteins13. Irf1 is also a transcription factor for iNOS, which
has been implicated in delayed APC 40,88. Knockout of Irf1 was recently shown to
improve outcomes in a mouse model of ischemic stroke 86,89. Basigin, also known as
extracellular matrix metalloproteinase inducer (EMMPRIN), neurothelin and cluster of
differentiation 147 (CD147), is a membrane bound protein of the immunoglobulin
superfamily. Through an interaction with cyclophilin A (CypA), basigin has been shown
to be an important regulator of neutrophil infiltration in a mouse model of lung injury 90.
Blocking the interaction of basigin and CypA lead to a 50% decreased neutrophil
infiltration at the site of injury and reduced tissue pathology 90. Finally, MT- I + II have
also been shown to modulate inflammatory response in rat brain. In the rodent model of
multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), intra-peritoneal
administration of MT I + II was shown to reduce levels of the proinflammatory cytokines
TNF-alpha and IL-6 91 while metallothionein knockout was associated with increased
levels of proinflammatory cytokines IL-1, IL-3, IL-6, IL-12, TNF-alpha, lymphotoxinalpha, macrophage activating factor and ICAM-185.
In addition to its role in modulating inflammatory response, basigin has other
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reported roles that could potentially contribute to either increased ischemic damage or to
protection 92. In its role as an inducer of matrix metalloproteinases, it is thought to play a
role in tissue remodeling following ischemic damage in rat heart93 and brain 94 and has
been associated with negative outcomes. Upregulation of basigin and the associated lactic
acid transporters MCT-1 and MCT-4 have been reported to protect against lactic acid
damage in neuronal and cardiac tissue during ischemia 95,96. Finally, in addition to
regulation of neutrophil infiltration, basigin/CypA complexes have been reported to
protect neurons from ischemic and oxidative stress 97. Interestingly, the basigin/CypA
interaction has been found to activate ERK1/2, p38MAPK, SAPK, and AKT: proteins
that are widely accepted to play a role in early preconditioning 92 31.
Disruption of energy pathways is a core part of the pathology of ischemic injury
11

. Four of the co-regulated genes on our arrays (Vdac2, Prkab1, Slc25a3, and G6pc)

have been shown to participate in the monitoring and regulation of energetic pathways.
Vdac2, in addition to its role in apoptosis, helps to regulate the ingress and egress of
small metabolites, including ATP and ADP from the mitochondrial space 31. Protein
kinase, AMP-activated protein (Prkab1) has been shown to be involved in nutrient
sensing in conjunction with Akt and mTOR and is regulated by p53 in a stress-dependent
manner98. Slc25a3 is a mitochondrial transport protein that is involved in the transport of
inorganic phosphates into the mitochondrial space 99 and is therefore directly involved in
regulating mitochondrial ATP production. Glucose-6-phosphatase is an endoplasmic
reticulum protein that is involved in conversion of D-glucose-6-phosphate to D-glucose
and inorganic phosphate in liver and kidney cortex 100.
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In conclusion we identified a number of genes that were differentially expressed
in rat liver kidney and heart following a clinical dose of isoflurane. Consistent with our
prediction, there were a number of genes that were differentially regulated in a number of
tissues. In order to assess functional roles for these molecules in the context of ischemic
injury, further functional assays will have to be performed. For our second study, we
selected two of the genes from our list, metallothioneins I + II, for further investigation
into their role in delayed anesthetic preconditioning.
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Table 2.1. Primer and probe sets for QRT-PCR confirmation of selected DNA microarray data.
Gene
Ccnd1
Prdx5
Mt2
Ptprc

Description
CyclinD1
Peroxiredoxin 5
Metallothionein 2
Protein tyrosine
phosphatase,
receptor type, C

GenBank ID
D14014
AF110732
NM_008630
M10072

Forward Primer
GGGTCTGCGAGCCATGCT
GCTCCGTGCATCGGCTACTT
GCAAATGCACCTCCTGCAA
ACCTACATTGGAATTGATGCCATGCT

Reverse Primer
CCGCATGGATGGCACAAT
ACCGCGGCACTGCTGAA
ACACAGCCCTGGGCACATT
CCTCCACTTGCACCATCAGACA

FAM/TAMRA Probe
AGACCTGCGCGCCCTCCGTTT
AGCAGGCCGGAAAGGAGCAGGTTG
AAAGCTGCTGCTCCTGCTGCCCC
GAAGCAGAGGGCAAAGTGGATGTCTATGG
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All sequences shown are 5'-3'. Probes sequences were modified with a 5' 6-carboxy fluorescein and at the 3' end with a 6-carboxy-tetramethyl rhodamine.
Primers and probes were designed in Primer express 1.0 (Applied Biosystems Inc, )

Ontology

Full Name

Code

GenBank
accession

Potential roles in protection

Liver Kidney
Level Level

Heart
Level

Apoptotosis and necrosis, energy
Unknown
neuronal growth and guidance
DNA repair, cell cycling
cellular remodelling

metabolism
voltage-dependent anion channel 2
multiple EGF-like-domains 8
ninjurin 2
cyclin-dependent kinase 7
basigin (EMMPRIN/Ox47/CE-9)
solute carrier family 25 (mitochondrial carrier,
phosphate carrier), member 3
sterol-C4-methyl oxidase-like

Vdac2
Megf8
Ninj2
Cdk7
Bsg

AB039663
AB011534
AB040815
X83579
NM_012783

regulation of ATP consumption and regulation of apoptosis
too little data
tissue regeneration, neurite outgrowth
inhibits rnaPII, thiol center suggests role in oxidative stress
May play a role is basement membrane remodelling

1.53
-1.25
NSR
-1.61
2.22

1.23
NSR
-1.22
-1.38
1.66

NSR
-1.36
-1.33
NSR
NSR

Slc25a3
Sc4mol

M23984
D50559

1.46
-1.58

1.26
NSR

NSR
-1.25

Lpl
G6pc
Exoc6
Avpr1a

NM_012598
NM_013098
NM_019277
Z11690

-1.50
2.82
1.20
NSR

NSR
1.43
NSR
-1.29

-1.23
NSR
1.27
-1.24

Copb2

AF002705

-1.20

NSR

NM_019623

1.61

1.29

NSR

Gne

Y07744

1.38

1.21

NSR

Cell signaling
Cell signaling
Nucleotide metabolism
Unknown

fatty acid binding protein 5, epidermal
Rab acceptor 1 (prenylated)
ureidopropionase, beta
tripartite motif-containing 17

Fabp5
Rabac1
Upb1
Trim17

U13253
AF025506
M97662
AF156272

-1.74
1.74
1.32
2.21

NSR
1.31
1.39
1.53

-1.27
NSR
NSR
NSR

Cell death, exocytosis, cell signaling
phospholipase D1
Protein transcription
ribosomal protein L8

Pld1
Rpl8

U69550
X62145

intracellular vesicle trafficking
role in curtailing inflammation, sexual dimorphism in expression between males and
females
encourages neurite outgrowth, sialation of sugars. . . Involved regulating growth and
development, bind alpha actin
shown to be downregulated durig liver regeneration, fatty acid metabolism,
regulated by retinoic acid signaling, beta catenin/notch signaling
beta catenin signaling, role in liver regeneration
Uracil and thymidine catabolism
zinc ion binding, found mostly in Testis, function largely unknown
involved in insulin sensitivity, important for calcium regulate exocytosis, important for
egf signaling, regulation of cell death
Human 60S ribosome homolog

-1.24

Cyp4f1

Neuronal growth and guidance

lipoprotein lipase
glucose-6-phosphatase, catalytic subunit
exocyst complex component 6
arginine vasopressin receptor 1A
coatomer protein complex, subunit beta 2 (beta
prime)
cytochrome P450, family 4, subfamily f,
polypeptide 1
glucosamine (UDP-N-acetyl)-2-epimerase/Nacetylmannosamine kinase

involved in energy-linked phosphate transport
axonal guidance
conversion to fatty acid metabolism/ ??? But regulated against what would be
expected
energy metabolism
Protein secretion
results in increased cytoplasmic calcium in astrocytes

NSR
1.55

-1.20
1.25

-1.53
NSR

Na, K transport and water regulation
ATPase, Na+/K+ transporting, alpha 1 polypeptide
protein kinase, AMP-activated, beta 1 non-catalytic
Energy metabolism, Apoptotic pathways
subunit
Cas-Br-M (murine) ecotropic retroviral
DNA damage response
transforming sequence b
transcription elongation factor B (SIII), polypeptide
2
Transcription regulation
DNA damage response
interferon regulatory factor 1
Vessicle transport
SV2 related protein
Unknown
heart endothelial unknown protein
Unknown
Rat insulin-like growth factor I
Unknown
proline-rich protein 15

Atp1a1

M28647

Prkab1

energy metabolism
Neuronal growth and guidance
energy metabolism
Energy metabolism
Secretory
Ca2+ modulation
Vesicular trafficking
Inflammatory response

Vessicle transport
Bilirubin catabolism
Apoptosis
Zinc Metabolism
Zinc Metabolism

1.66

1.25

NSR

U42411

Na, K transport, regulation of water, activity depends on redox state, with ouabain,
catalytic subunit) bind inositol 1,4,5 triphosphate causing ca survival signal
involved in gluconeogenesis, involved in sensing nutrient availability, regulates IGF1-AKT-mTOR in P53 dependent way

-1.45

NSR

-1.21

Cblb

AF199504

egf (epidermal growth factor) regulation, cell signaling

1.24

1.27

NSR

Tceb2
Irf1
Svop

L42855
NM_012591
AF060173
U44844
M81184
NM_012632

1.23
-1.72
-1.41
1.63
-1.22
1.74

1.35
NSR
-1.10
NSR
-1.25
NSR

NSR
-1.27
-1.24
1.25
NSR
1.20

X52772

increases rate of RNA polymerase transcription
cytokine induced iNOS regulation, DNA damage reponse
synaptic vessicle transport, central nervous system only
Unknown
unknown
unknown
synaptotagmin, vesicular transport, ca dependent exocytosis, ca sensing forr fast
synaptic transmission

1.62

1.31

NSR

S70360
AF279910
NM_008630
J00750

hepatic bilirubin catabolism
downregulated in cardiac, blocked by preconditioning, pro-apoptotic
Induced by MCAO and may be protective
Induced by MCAO and may be protective

1.26
-1.22
3.77
2.31

-1.24
-1.22
1.41
1.35

-1.11
NA
NA
NA

Prp15

synaptotagmin I
Syt1
UDP glucuronosyltransferase 1 family, polypeptide
A1
Ugt1a1
Bcl2-associated death agonist
Bad
metallothionein 2
Mt2
metallothionein 1a
Mt1a
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Table 2.2. Genes differentially regulated in rat liver, kidney and heart following a clinically relevant isoflurane exposure.
Selected genes had to be present on at least 7 of 9 arrays, found to have statistically significant (P ≤ 0.05) differential regulation
compared to a pooled control in at least two separate tissues, and be regulated at least 1.2 either up or down in each of those tissues.

Figure 2.1. Venn diagram of genes differentially expressed in rat liver kidney and
heart. Represented genes were differentially expressed on at least 7 of 9 arrays for each
tissue, were significant (p < 0.05), and were differentially regulated in more than one
tissue.
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Figure 2.2. Comparison of differential regulation of three genes by DNA
microarray and by QRT-PCR. The trendline represents perfect agreement between
DNA microarray and QRT-PCR results. The same sample of RNA was used for both
micrarray and QRT-PCR experiments. Microarray values shown are the average
“median of ratios” value from 9 independent arrays ± SEM. QRT-PCR values are the
average ± SEM of 3 separate trials for each gene after being normalized to our control
gene,
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CHAPTER 3
A ROLE FOR ROLE FOR METALLOTHIONEINS-I + II
IN ISOFLURANE PRECONDITIONING OF PRIMARY MURINE NEURONAL
CULTURES

Introduction

Given the potential for improved clinical outcomes, mechanisms of delayed
anesthetic preconditioning have been intensely studied 60. Since first being demonstrated
in rabbit heart 29, preconditioning by volatile anesthetics has been described in both in
vivo 40,101,102and in vitro 40,103 models, and in other tissues including the brain. In these
studies, inducible nitric oxide synthase 40,102, intracellular calcium 103mitogen-activated
protein kinase 102,103, and a variety of mitochondria related proteins19 have all been
implicated in the cellular mechanisms of APC. Despite these findings, a complete
understanding of the pathways involved in APC has yet to be elucidated.
Recent work from our lab identified metallothionein I + II genes (MT-I + II) as
among those significantly regulated in rat liver, kidney and heart following a 90min 2%
isoflurane exposure104. Furthermore, Carmel et al., 105, found MT-I + II mRNAs were
strongly and rapidly upregulated in response to ischemic preconditioning of rat spinal
cord. Metallothioneins-I + II are small (6000-7000 Daltons), cysteine-rich metal-binding
proteins and have been shown to protect against a wide range of stresses including
cardiac ischemia-reperfusion51and focal cerebral ischemia106. To date, the relationship
between MT-I + II proteins and anesthetic preconditioning remains to be explored. In the
current study, we examine protective characteristics of delayed isoflurane
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preconditioning in dissociated neuronal culture and the role that MT-I + II play in
conferring APC-mediated protection.

Methods
Animal Care
C57BL/6J (C57), 129S7/SvImJ (129S, control strain for MT-I + II knockout)
mice and 129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J (MTKO, metallothionein-I + II knockout
strain) were purchased from Jackson Laboratories (Bar Harbor, ME) and breeding
colonies established. Animals were kept under a standard 12/12 light/dark cycle at room
temperature and given access to food and water ad libitum. Animals were housed and all
experiments carried out with protocols approved by Smith College Institutional Animal
Care and Use Committee (Northampton, MA, USA) according to the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health, 1996).

Primary neuronal cultures
Neonatal mouse pups at postnatal day 1-3 (P1-3) were sacrificed by decapitation.
Cortices were dissected out, minced and placed in modified DMEM (80% Dulbecco’s
modified eagle medium; 10% fetal bovine serum, 10% F12 medium and 10 µg/ml
Pen/Strep). Tissue was digested in dilute Trypsin/Hanks Balanced Salt Solution (1:1) for
25 min, quenched with 50% horse serum prior to brief centrifugation to pellet tissue
Tissue was triturated with a fire-polished Pasteur pipette, filtered through a
Steriflip100µM nylon filter (Millipore; Billerica, MA) and plated onto poly-lysine
coated wells, or in the case of immunofluorescence microscopy, on poly-lysine coated
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glass coverslips. Cultures were maintained in an incubator (5% CO2, 95% air) at 37˚ C
for 10-12 days in vitro.

Isoflurane Preconditioning
Isoflurane preconditioning was accomplished by placing cultures (10-12 days in
vitro) inside a humidified exposure chamber with inlet and exhaust ports for the
anesthetic mix.

The entire exposure chamber was housed within a 37˚ incubator. A

mixture of 95% air/5% carbon dioxide was passed through an Isotec 3 isoflurane
vaporizer (GE Healthcare; Waukesha, WA) to deliver 1.5% isoflurane/93.5% air/5%CO2
to the chamber at a rate of 0.4 l/min for 3 hrs. Following APC, cells were washed 1X
fresh media was added prior to replacing cells in a standard humidified carbon dioxide
incubator. For controls, all media changes were performed in parallel with
preconditioned cultures.

Oxygen-Glucose Deprivation
Oxygen glucose deprivation (OGD) exposures were carried out as previously
described40 with some modifications. Cell cultures were washed 4 times with zeroglucose DMEM (Invitrogen, Carlsbad CA) and placed in a humidified anoxic chamber at
37˚C. The chamber, was evacuated and flushed 3 times with 90% N2, 5% H2, and 5%
CO2 in order to remove oxygen. To further reduce oxygen levels, a palladium catalyst
was also maintained in the chamber to react any remaining oxygen with the hydrogen.
Non-OGD samples were treated the same as OGD receiving samples, but were washed
with standard glucose-containing culture media.
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Quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) of
MT-I + II RNA levels
Cells were harvested using a cell scraper, pooled, pelleted by centrifugation, and
then added to Trizol reagent (Invitrogen) and stored at –20˚C for further processing. Total
RNA for QRT-PCR analysis was isolated from Trizol/tissue homogenate using Qiagen
Rneasy Mini kits (Qiagen: Valencia, CA). In brief, chloroform was added to the
Trizol/tissue homogenate and the aqueous phase was removed, mixed with 70% ethanol
and placed on a separation column. After repetitive washes and elution in RNAse–free
water, RNA was quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies; Rockland, DE). All samples yielded 260/280 absorbance ratios between
1.9 and 2.1.
QRT-PCR of MT-I and MT-II messenger RNA (mRNA) was performed using a
mouse-modified primer/probe set (FAM/TAMRA) described by Tomita et al. 107. Primers
and probes were synthesized by IDT inc (Coralville, IA): MTI forward 5’CTGCTCCACCGGCGG-3’, MT1 Reverse 5’-GCCCTGGGCACATTTGG-3’; MTI taqman

probe: 5’-CTCCTGCAAGAAGAGCTGCTGCTCCT-3’; MTII forward 5’TCCTGTGCCTCCGATGGATC-3’ ; MTII reverse 5’-GTCGGAAGCCTCTTTGCAGA-3’;

MTII taqman probe 5’-AAAGCTGCTGCTCCTGCTGCCCC-3’; LCA1 (leukocyte common
antigen 1) forward 5’-ACCTACATTGGAATTGATGCCATGCT-3’; LCA1 reverse 5’CCTCCACTTGCACCATCAGACA-3’; LCA1 taqman probe 5’GAAGCAGAGGGCAAAGTGGATGTCTATGG-3’. All QRT-PCR reactions were carried out

on an Applied Biosystems 7700 Taqman instrument (Applied Biosystems; Foster City,
CA) in single tubes. The QRT-PCR reaction mix was comprised of 1X PCR buffer
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(Invitrogen, Carlsbad, CA), 6mM MgCl2, 0.67 mM each dinucleotide, 6.75 pmols each of
forward and reverse primers, 1.5 units Superase-in (Ambion; Austin, TX), 15 units
Superscript II (Invitrogen), 0.75 units Platininum Taq Polymerase (Invitrogen) to a final
volume of 15µl. Each reaction was run one cycle of 30’ at 42˚, 1 cycle of 3’ at 95˚ and
40 cycles of 1’ at 60˚ and 20” at 95˚. QRT-PCR for the normalization gene, mouse
protein tyrosine phosphatase, receptor type C (PTPRC), was performed as above but
using PTPRC primers and probe set. Universal mouse RNA (Stratagene, La Jolla CA)
was used to create a standard curve for each gene of interest and for the normalization
gene, PTPRC. Gene reactions were run in triplicate, averaged and normalized to PTPRC.

Lactate Dehydrogenase assay for determination of cellular toxicity
Global cellular toxicity was assessed using the CytoTox LDH assay (Promega,
Madison WI). Briefly, following experimental treatment, 50µl media were removed
from each culture well and placed in a separate well-plate. 50 µl of LDH assay solution
was added to each well and allowed to incubate in the dark at room temperature for 30
min. At the end of the incubation period, 50µl stop solution was added and color change
was measured at 490nm on a Bio-TEK µQuant UV/Vis plate reader (BioTEK
Instruments; Winooski VT). Net color change was determined by subtracting the average
value of media-only wells from experimental values.
Lactate dehydrogenase release data were first normalized using the equation
((LDH valueIndividual well)/ (Control Average Experiment)) in order to compare results between
different experiments. Values for each condition were further transformed by calculating
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average percent level of protection compared to control using the equation: (100- (100 *
(Experimental/Control)).

Microtubule associated protein-2 (MAP2)/Glia fibrillary associated protein (GFAP)
colorimetric assays for determination of cellular toxicity
MAP2 and GFAP colorimetric assays were performed following a modified
protocol described by Carrier et al. 108. Briefly, treated and control cultures were washed
3 times in phosphate buffered saline (PBS) and then fixed at room temperature in 4%
paraformadehyde in 0.1% sodium phosphate (pH 7.4) for 30 min. Fixed cells were
subsequently permeablized with 0.4% Triton-X 100 in PBS for 10 min at room
temperature. Cells were then washed 3 times in PBS, and blocked for 30 min in 10%
bovine serum albumin (Sigma-Aldrich, St. Louis, MO) at room temperature. Either
rabbit anti-GFAP (sc-65343, Santa Cruz Biotechnology Inc, Santa Cruz, CA) or antiMAP2 (sc-20172; Santa Cruz Biotechnology Inc) primary antibody in 3% bovine serum
albumin/0.4% Triton-X100 in PBS (1:100) was added to fixed cultures and allowed to
hybridize overnight at 4˚C. Fixed cells were then washed 3 times in 0.5% Tween/PBS
and hybridized for 2 hrs at room temperature with horse radish peroxidase- conjugated 2˚
antibody at 1:2000 (sc-2004; Santa Cruz Biotechnology) in 1% bovine serum
albumin/0.4% Triton-X 100 in PBS. Cell survival was monitored by measuring the horse
radish peroxidase-catalyzed conversion of Amplex Red to resorufin (Invitrogen) with
1mM H2O2 (1mM; Sigma) in 50mM phosphate buffer. Samples from each well were
transferred to a 96 well plate and absorbance (at 565 nm) measured on a Bio-TEK
µQuant UV/Vis plate reader.
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MAP2, GFAP, MT-I + II immunofluorescence microscopy for determination of MT
localization.
Cells for localization studies were grown on poly-lysine coated glass coverslips.
Preparation for labeling was performed as described for colorimetric assays until the
secondary labeling stage. Cultures were labeled with primary antibodies for MAP2
(rabbit anti-MAP2 polyclonal; sc-20172; Santa Cruz Biotechnology), GFAP (rabbit antiGFAP polyclonal; ab16997-1; AbCam) and MT-I + II (mouse anti-MT-I + II
monoclonal; E-9; Zymed). The E9 clone has been demonstrated to be specific for MT-I +
II and not to label other metallothioneins 109. Secondary labeling was performed using
fluorescent dye-conjugated 2˚ antibodies (Alexa 488 goat anti-rabbit and Alexa 594 goat
anti-mouse; Invitrogen; 1:4000) in 1% bovine serum albumin/0.4% Triton-X100 in PBS.
Nuclei were counterstained for 3 min with 1x Hoechst (Invitrogen). Coverslips were
mounted on slides and visualized using an Olympus BX51 epifluorescence microscope
(Olympus America Inc, Center Valley, PA).

siRNA Knockdown of MT-I + II
A Dicer-substrate (DsiRNA) duplex that targets both MT-I and MT-II and sham
duplex (designed not to target any genes) were obtained from Integrated DNA
Technologies, Inc. (Coralville, IA). RNA sequences for the metallothionein-I + II
knockdown duplex strands were AGAACUCUUCAAACCGAUCUCUCGT and
ACGAGAGAUCGGUUUGAAGAGUUCUAG. Sequences for the scrambled sham duplex

were not available from Integrated DNA technologies. Cultures 10-12 days in vitro were
transfected with siRNA constructs following instructions for use of TransPass R1
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transfection reagent (New England Biolabs, Ipswich MA). In brief, for each well, 400µl
of high-glucose serum-free DMEM (Invitrogen) was mixed for 20 min with 1.0 µl
transfection solution A, 2.0 µl transfection solution B, and 20 µM duplex RNA to bring
the final siRNA concentration to 5-10 nM. Cells were then washed 4 times with serumfree high-glucose DMEM (Invitrogen). Transfection mixture was added and cultures
were returned to the incubator. After 2 hrs, the transfection mixture was removed and
replaced with standard media. Cells were allowed to recover for 72 hrs prior to further
treatment. Transfection efficiency was assessed using immunofluorescence microscopy
to visualize the transfection of a fluorescein-labeled siRNA control (15 nM, FluoresceinsiRNA Transfection Control; New England Biolabs). siRNA knockdown of MT-I + II
was assessed by QRT-PCR under both basal and under MT-stimulating conditions (20
µM ZnCl2, 12 hrs prior to harvest; 110, 111. Cells were treated with sham siRNA for all
control experiments.

MT-I + II protein transfection
Cells were transfected with either exogenous MT-I + II purified from horse liver
(Sigma) or with a similar sized control protein (insulin oxidized ß-chain, Sigma) using
ProteoJuice transfection reagent (Novagen, San Diego CA). Briefly transfection reagent
and protein were mixed 1:2 (v:w) in 25 µl of serum-free DMEM and incubated at room
temperature for 20 min. Meanwhile cells were washed 4 times with serum-free DMEM
and left in serum-free DMEM. The transfection mixture was added to each well to
achieve a final protein concentration of 1.6-3.2 µM and cells were returned to the
incubator at 37˚C for 2 hrs. Transfected cells were washed 4 times in no-glucose DMEM
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and immediately placed in an anoxic chamber for OGD treatment. OGD toxicity was
assessed by LDH.

Statistics
All statistics were performed in SPSS 9.0 (SPSS Inc, Chicago IL). ANOVA
analyses were applied to data in Figures 3.1, 3.2, and 3.3 with Bonferroni post-hoc
analyses where applicable (Figure 1). Figure 4 required no statistics. Figure 5 was
analyzed by ANOVA. Two-tailed Student’s t-tests were applied to the data in Figures
3.1, 3.3, 3.5, 3.6 and 3. 7. Significance level was set at p < 0.05 unless stated otherwise.

Results
Isoflurane induced delayed protection against subsequent OGD-mediated toxicity in
mouse cortical cultures.
Isoflurane preconditioning has been shown to protect against ischemic injury in
rat brain providing improved histologic and neurologic outcomes one month following
preconditioning/ischemia 39 and in neuron-enriched cortical cultures 24 hrs following
isoflurane preconditioning 40. In order to determine if isoflurane preconditioning
protected over an extended period in culture conditions, we evaluated OGD toxicity in
mixed cortical cultures at 24, 48, 72 and 96 hrs post-preconditioning (Figure 3.1). A 3hr
pretreatment with 1.5% v/v isoflurane (a clinically relevant exposure) provided protection
that was significant (two-tailed Student’s t-test; p < 0.01) compared to paired, nonpreconditioned controls for all time points. In detail, at 24 hrs the protection amounted to
11.6 ± 7.9% (n=21), increasing to peak protection of 37.5 ± 2.5% at 72 hrs (n=21). The
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effect persisted and was still robust at 96 hrs (33.4 ± 1.6%; n=32). These data are
consistent with isoflurane conferring delayed preconditioning via a direct
pharmacological mechanism in dissociated primary cultures (see also Kapinya et al. 40).

Isoflurane preconditioning protects neurons and glia against OGD toxicity
To determine which cell lineages were protected against OGD by isoflurane
preconditioning, we used an Amplex red-based immunoassay (Figure 3.2) to assess
neuronal and glial survival following 3hrs OGD. Although 3hrs OGD was toxic to both
neuronal and glial populations, neurons were particularly sensitive to this treatment with
survival rates of only 39.6 ± 8.6% vs 79.0 ± 4.1 % (n=16) for glial cells. Neurons were
also more responsive to isoflurane preconditioning showing recovery to a 84.9 ± 4.3%
(n=16) survival rate i.e . ~127% increase in survival. To a lesser extent glial cells were
also protected with a relative increase in survival rate of only ~22% (Figure 3.2). For
neuronal populations, a 2x2 ANOVA analysis showed significant main effects of OGD
and of isoflurane preconditioning (APC) with a significant interaction between these
variables (p < 0.01). This interaction indicates the effectiveness of APC in counteracting
OGD-mediated cell death and is supported by a Student’s t-test that confirmed a
significant (p<0.01) difference between ‘OGD alone’ and ‘APC + OGD’ conditions
(Figure 3.2). For glial cells, the 2x2 ANOVA analysis revealed significant main effects
of OGD and of isoflurane preconditioning (APC) (p < 0.05) however there was no
significant interaction between these variables (p=0.53) . The lack of a significant
interaction can be interpreted to mean that isoflurane preconditioning is not effective in
protecting glia against OGD. However, a Student’s t-test comparing the ‘OGD alone’

44

and ‘APC + OGD’ conditions revealed a significant (p<0.01) difference between these
groups suggesting that APC was effective but that the level of OGD toxicity was not as
pronounced in this cell population.

MT-I + II protein transfection provides protection against OGD-mediated toxicity
Previous studies have implicated MT-I + II in neuronal protection against
ischemia (see Carmel et al. 105, and Wakida et al. 106 ). Kennette et al. 112 determined that
basal levels of metallothioneins were protective against certain toxins (e.g. tertbutyl
peroxide) while for other toxins (e.g. cadmium and cisplatin) MT levels had to increase
above basal levels for protection to occur. To discern in our system whether increased
MT protein levels provided direct protection against OGD, we transfected cultures with
exogenous MT-I + II protein prior to a 3 hr OGD challenge and then assessed toxicity by
LDH (Figure 3.3). Compared to transfection with a similarly-sized control protein
(oxidized insulin ß-chain), MT protein transfection conferred protection against 3hr
OGD, rising from 2.9 ± 2.0% protection at 1.6 µM MT (not significant; n=8 ) to
significant protection of 33.2 ± 3.1% (p < 0.001; n= 8) with 3.2 µM MT . In summary,
these data confirm previous reports that metallothioneins are protective against ischemic
toxicity in neuronal tissue 113.

MT-I and MT-II gene expression increased following isoflurane-mediated
preconditioning.
Given the precedent for regulation of MT gene expression following an ischemic
episode 12 or an anesthetic exposure 104, we examined whether MT-I and MT-II were
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induced in mouse mixed neuronal/glial following preconditioning with a 3hr, 1.5%
isoflurane exposure. Both MT-I and MT-II were rapidly upregulated with increases in
mRNA levels observed as early as 3 hrs (Figure 3.4). For both metallothioneins-I + II,
mRNA levels peaked at ~12 hrs with levels that were 2.2 ± 0.2 and 2.8 ± 0.4 fold the
non-preconditioned cultures for MT I and MT II, respectively. Compared to untreated
paired controls, MTI mRNA fold changes were significant (two-tailed Student’s t-test; p
< 0.05) at 6 and 12 hrs and MTII mRNA fold changes were significant at 3, 6 and 12
hrs. These data are consistent with those described by Carmel et al. for ischemicpreconditioning of rat spinal cord 105 and indicates that metallothioneins are also
regulated in response to isoflurane preconditioning. Although it would be preferable to
establish the timecourse of the changes in protein levels post-APC due to the small size
and nature of the metallothioneins (e.g. highly hydrophilic, number of cysteine residues)
we were unable to resolve metallothionein protein levels at the sensitivity required (see
also Lu et al.) 114.

siRNA knockdown of MT-I + II enhances OGD-mediated toxicity and attenuates
isoflurane-induced protection.
In order to assess the protective role of MT-I + II in isoflurane preconditioning,
prior to repeating the preconditioning/OGD regimen, we transfected cultures with either a
sham siRNA construct or an siRNA construct that targeted both MT-I and MT-II . We
first determined the degree of MT-I and MT-II mRNA knockdown using QRT-PCR
(Figure 3.5 A). MT-I + II mRNA levels were assessed under basal and under MT
stimulating conditions (addition of 20µM ZnCl2, see Kim et al. 110). Though we were able
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achieve only partial knockdown of either gene (Figure 3.5 A), MT-I and MT-II mRNA
levels were diminished in a dose-dependent manner by MT-siRNA transfection. Zinc
stimulation and siRNA knockdown both showed greater effect on MT-II than on MT-I.
We assessed the effect of sham knockdown (ShamKD) or metallothionein
knockdown on isoflurane-mediated protection against 3hr OGD using an LDH assay
(Figure 3.5 B). Isoflurane -preconditioned ShamKD cultures demonstrated substantial
protection (17.5 ± 5.2%, n=27), similar to our findings for WT C57 cultures.

ANOVA

analysis of the siRNA data revealed main effects of metallothionein knockdown (p <
0.05) and of APC (p < 0.01). However, there was no significant interaction found
between these variables (p=0.518). This implies that the partial knockdown of the
metallothioneins was not effective in reducing the protective influence of APC
significantly. However, metallothionein-I + II knockdown conditions without
preconditioning showed substantially increased OGD-mediated toxicity compared to
ShamKD (Figure 3.5 B). This suggests that MT-I + II below typical basal levels renders
cells particularly vulnerable to OGD insults. Due to the incomplete knockdown of MT-I
+ II in the siRNA experiments, we extended our study to perform APC/OGD
experiments with MT-I + II knockout mouse-derived cultures.

MT-I + II knockout abolishes isoflurane-mediated protection against OGD toxicity.
As a more definitive method of addressing the importance of metallothioneins to
isoflurane preconditioning, we compared treatments on cultures prepared from MTI + II
knockout mice (see Methods) to cultures derived from the background (129) strain
(Figure 3.6). Similar to our previous experiments with C57 mice (Figure 3.1),
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preconditioned background (129)-derived cultures showed significant protection (twotailed Student’s t-test; p < 0.001) against OGD toxicity (26.2 ± 3.6%; n=16) as compared
to paired non-preconditioned samples. By contrast knockout-derived cultures (MTKO)
showed no protection from isoflurane preconditioning (1.5% ± 3.7%; n=25, Figure 3.6
B). Both 129 WT and MTKO cultures were assessed by LDH for toxicity from isoflurane
preconditioning alone. Preconditioned 129 WT cultures showed LDH levels of 97 ± 11%
of untreated cultures and MTKO cultures showed LDH levels 124% ± 19% their
untreated counterparts at 48 hrs post-isoflurane exposure (n=16). There was no
significant difference between treated and untreated cultures in either 129 WT or MTKO
cultures (two-tailed Student’s t-test, p = 0.86 and p =0.49 respectively). These data
provide compelling evidence of a critical role for metallothioneins in isoflurane–mediated
preconditioning.

Metallothionein-I + II proteins are primarily localized to neuronal cytoplasm in
mouse neonatal cortical cultures.
In light of our finding that APC provided more protection from OGD to neurons
rather than glia, we determined the cellular localization of MT-I + II proteins (Figure
3.7). Previous studies in mouse brain have shown metallothioneins-I + II to be localized
primarily in glial cells 115,116, 106. Here we used immunofluorescence microscopy to
assess the colocalization of a monoclonal MTI + II antibody with either neuron-specific
MAP2 antibodies or glial-specific GFAP antibodies. In C57- and 129-derived cells the
metallothionein antibody colocalized strongly with MAP2 labeled cell bodies indicating
strong neuronal localization (Figure 3.7 A). GFAP-labeled cells showed metallothionein
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co-localization to a lesser extent (data not shown). Neither MT knockout-derived cultures
nor 129 wild type (WT) cultures coincubated with 10 µM horse MT-I + II protein
demonstrated measurable MT labeling, consistent with MT-I + II specific labeling
(Figure 3.7 B and C).

Discussion
Delayed anesthetic preconditioning has been shown to be a powerful tool for
improving both histological and clinical outcomes against ischemia-mediated toxicity in a
number of tissues 101, 117. Given the relative safety of preconditioning with anesthetics vs
surgically-induced ischemia 59, there is emerging interest in anesthetic preconditioning.
In this study, we used a dissociated cortical neuronal culture model to investigate the
direct pharmacological effects of isoflurane preconditioning and the role that MT-I + II
play in mediating that protection. An in vitro dissociated tissue culture model of neuronal
APC/OGD presents a number of advantages over in vivo models including the ability to
measure direct pharmacological effects of the anesthetic agent while avoiding the
confounding influences of hemodynamics, cardiac depression and other anesthesia
mediated physiological factors. An in vitro model also provides more flexibility for
manipulation and direct observation of outcomes in studying molecular mechanisms.
Inevitably, however, a dissociated culture model has limitations. For instance, the in
vitro OGD model cannot be used to assess system-wide effects of ischemic injury such as
inflammatory and immune response to injury. Furthermore focal ischemia models enable
observations of long-term outcomes in vivo. Despite these constraints, we have shown
that dissociated culture with OGD is a useful model for studying APC and OGD, and that
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the time course of protection mirrors that of in vivo models 40, 117. In future, it will be
necessary to follow up our experiments with studies on the role of metallothioneins
during anesthetic preconditioning in vivo. Moreover, as MTs can be induced through
various conditions 85, this work may have important implications for improved clinical
outcomes.
The principle findings of our study are as follows: 1). Pretreatment with 1.5%
isoflurane provided robust protection against OGD toxicity that peaked 72 hrs following
isoflurane exposure. 2). OGD was more toxic to neurons than to glia although
preconditioning with isoflurane significantly reduced toxicity in both populations. 3.)
Exogenous MT protein supplementation was directly protective against OGD toxicity. 4).
MT-I + II mRNAs were rapidly and robustly induced by treatment with clinicallyrelevant doses of isoflurane.

5.) siRNA knockdown of MT-I + II diminished isoflurane

diminished protection against an OGD insult. 6). MT-I + II gene knockout abolished
isoflurane mediated protection and rendered cultures more susceptible to OGD than WT
cultures 7.) MT-I + II localized to neuronal cell bodies, although were also seen in glial
cytoplasm. Combined these data argue for an important role of metallothioneins-I + II in
isoflurane-mediated protection against OGD. To our knowledge, this is the first time
metallothioneins-I + II have been revealed as important mediators of isoflurane
preconditioning.
There are several reports supporting a protective role of MT-I + II in a number of
tissues. In particular, MT-I + II have been implicated in protection against ischemic
injury in brain 106, 118, heart 51,119 and kidney 120. Campagne et al. 118found MT
overexpressing mice not only had better histologic outcomes, but also significantly
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improved motor performance 3 weeks following focal cerebral ischemia/reperfusion.
Wakida et al. 106 found erythropoietin-induced MT-I + II reduced infarct area and volume
at 24 hrs following permanent middle carotid artery occlusion (MCAO) damage in rat
brain. Of direct relevance to our study, Carmel et al. 105 found MT-I + II mRNAs were
rapidly induced in rat spinal cord following brief ischemic preconditioning. Together
these data complement our findings that MT-I + II are rapidly induced following
isoflurane preconditioning and that the increased MT levels provide protection against
subsequent ischemic injury.
A surprising result was the localization of MT-I + II to neuronal cell bodies along
with weaker glial staining (Figure 3.7). While this localization correlates well with the
robust APC-mediated neuronal protection (Figure 3.2), it contrasts with previous reports
that metallothioneins-I + II localize primarily within glia in the brain with little to no
expression in neurons 115. These localization differences may be accounted for by a
number of experimental variations including developmental stage of our cells, differences
in structure of cells grown in culture vs in vivo, or differences in fixing procedures (see
Hidalgo et al., 2001115). Neuronal localization may be accounted for by recent work by
Chung et al. 121, who found MT-I + II can be exported by astrocytes and readily taken up
and utilized by neurons.
While our study demonstrated that MT-I + II can be protective against OGD, the
mechanism by which MT-I + II confer this protection remains to be determined.
Metallothioneins are small (~6000-7000 Da) metal-binding (primarily Zn2+and Cu2+)
proteins that are expressed throughout the body. They exhibit a number of cellular
activities that could potentially account for their protective role against ischemia (see
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Penkowa, 85). These roles include modulation of cellular redox, immune defense
response, mitochondrial respiration, angiogenesis, cell-cycle progression, cell survival
and differentiation. An intriguing role for MTs in preconditioning is as a critical
component of the nitric oxide signaling cascade 122 that has been identified as essential
for induction of delayed isoflurane-induced preconditioning in heart. 117. Stitt et al., 123
studying nitric oxide signaling in mouse lung endothelial cells, showed that
metallothionein was essential for nitric oxide-mediated translocation of the transcription
factor MTF-1 (metal-responsive transcription factor 1) to the nucleus and for subsequent
upregulation of metallothionein. These data support a role for metallothioneins in nitric
oxide signaling during ischemic stress.
In addition to possibly participating in nitric oxide signaling, another potential
role for MT’s in APC-mediated protection is as an end effector of cellular protection.
This is supported by the findings, shown in Figure 3.3, in which transfection of
exogenous MT-I + II protein provided immediate protection against OGD damage. As an
end effector, MTs might act as antioxidants to detoxify reactive oxygen species produced
by the energy pathway imbalances of ischemia (see Penkowa 85). In support of this,
increased MT levels have been shown to decrease both reactive oxygen species levels
and peroxidation of cellular proteins and lipids 124. Furthermore the antioxidant effects of
MTs during mitochondria-specific oxidative stress have been shown to result in greater
protection than provided by Cu/Zn-SOD, glutathione peroxidase, Mn-SOD or catalase 53.
Alternatively, MT-mediated protection may depend on the central role metallothioneins
play in zinc homeostasis85. Approximately 3% of the mammalian proteome requires zinc
for some aspect of functionality with 40% of zinc binding proteins acting as transcription
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factors and the remaining 60% proteins involved in ion transport or as enzymes 125.
Through their role in zinc homeostasis, MTs may have pleiotropic effects in ischemic
tissue which affect a range of responses from transcription to ion homeostasis through
modulation of zinc availability throughout the cell.
In conclusion, this study describes an important role for metallothioneins-I + II in
isoflurane preconditioning against OGD. Based on the role that MT’s play in isofluranemediated delayed protection against OGD, our results implicate metallothioneins-I + II as
possible molecular targets for improving clinical outcomes during ischemic injury.
Further studies to clarify the mechanisms of metallothionein I + II action will be essential
for understanding metallothionein-mediated protection and their potential for protection
against ischemic injury. In the final study of the dissertation, we address a possible role
for metallothioneins in delayed anesthetic preconditioning as sensors in an oxidative
stress signaling pathway.
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Figure 3.1. Isoflurane induces delayed protection against oxygen glucose
deprivation in murine mixed neuronal and glial cultures. Lactate dehydrogenase
release (LDH) was used to assess oxygen-glucose deprivation (OGD)-mediated toxicity
in both untreated and isoflurane preconditioned (1.5% isoflurane; 3 hrs) cultures at 24,
48, 72 and 96 hours post preconditioning. Percent protection (mean ± SEM) was
calculated using the equation: 100-(100 x (Mean Test LDH/Mean Control LDH)). Protection is
reported as compared to days in vitro- matched controls. *Significance: (p<0.01, twotailed Student’s t-test). Inset indicates timecourse for experimental procedure.
**Significant difference between timepoints and ‘NS’ denotes No significant difference
for an ANOVA with Bonferroni post-hoc analysis (p<0.05).
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Figure 3.2. Neurons and glia are protected by isoflurane preconditioning. Mouse
cortical cell culture subpopulations were assessed for oxygen-glucose deprivation
(OGD)-induced toxicity and isoflurane-induced protection by immunolabeling for
neurons with horse radish peroxidase-conjugated antibodies to microtuble associated
protein -2 (MAP2) and for glia with glial fibrillary associated protein GFAP.
*Significance: (p<0.01, n=16, two-tailed Student’s t-test). Inset indicates timecourse for
experimental procedure.
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Figure 3.3. Transfection with exogenous metallothionein-I + II protein protects
primary cortical cultures against oxygen glucose deprivation -mediated toxicity.
Primary cortical cultures were transfected with 1.6µM or 3.2 µM metallothionein-I + II
(MT-I + II) protein or 3.2 µM oxidized insulin ß-chain (control). Toxicity was assessed
by lactate dehydrogenase release assay. *Significance: (p<0.001, two-tailed Student’s ttest). Inset indicates time course for experimental procedure.
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Figure 3.4. Metallothionein I and II mRNA levels are increased following isoflurane
preconditioning. Primary cortical cultures were preconditioned with 1.5% isoflurane for
3hrs. Cells were collected at 5 time points (T=0, 3, 6, 12, and 24 hrs) post-exposure, and
metallothionein-I (MT1) and metallothionein-II (MTII) mRNA levels were assessed by
quantitative reverse trancriptase-polymerase chain reaction (QRT-PCR), normalized to
protein tyrosine phosphatase, receptor type C (PTPRC) expression. *Significance: ( p <
0.05; n=5; two-tailed Student’s t-test).
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Figure 3.5. Metallothionein short interfering RNA reduces Metallothioneins I and
II mRNA levels in a dose-dependent manner and increases vulnerability to oxygen
glucose deprivation. (A) Quantitative reverse transcriptase-polymerase chain reaction
(QRT-PCR) was used to assess metallothionein I + II knockdown by a short interfering
RNA (siRNA) against metallothioneins-I + II (MTKD). A sham siRNA (ShamKD)
construct was used as the control. ZnCl2 was used to simulate metallothioneinstimulating conditions. (B) OGD-mediated toxicity was assessed by lactate
dehydrogenase release assay in mixed cortical cultures transfected with either ShamKD
or the MTKD siRNA constructs. See Results for discussion of significance (n=27).
Insets indicate time course for experimental procedure.
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Figure 3.6. Knockout of metallothionein-I + II genes abolishes isoflurane-mediated
protection against oxygen-glucose deprivation. Oxygen glucose deprivation (OGD)mediated toxicity was evaluated following 3hr, 1.5% isoflurane preconditioning in mixed
neuronal/glial cultures from A.) Background strain (129) and B.) Metallothionein-I + II
(MT-I + II) knockout mice (MTKO). *Significance: p<0.001, two-tailed Student’s t-test.
Inset indicates time course for experimental procedure.
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Figure 3.7. Metallothioneins-I + II localize to neuronal cell bodies cortical neuronal
cultures. Metallothionein-I + II (MT-I + II) localization was visualized by epifluoresence
microscopy. Cultures, 10 days in vitro, were labeled using a monoclonal antibody against
MT-I + II and a polyclonal antibody against microtube associated protein-2 (MAP2).
Secondary labeling was accomplished with alexafluor 488 or alexafluor 594 fluorescent
conjugates. A.) 129 cells, nuclei were stained with Hoechst. B.) MT-I + II knockout
cells. C.) 129 cultures, antibody pre-incubated with 10 µM horse MT-I + II protein to
show MT antibody specificity.
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CHAPTER 4
A ROLE FOR METALLOTHIONEINS I + II AS SENSORS OF
OXIDATIVE STRESS IN ISOFLURANE-MEDIATED DELAYED
ANESTHETIC PRECONDITIONING.
Introduction

Ischemic injury progresses via a complex cascade of events that includes
diverse, but intertwined ontological pathways 11. Recent studies have identified a range
of molecules that are involved in delayed anesthetic preconditioning including COX-2 48,
NF-Kappa B 41, PI3 kinase 55, K(ATP) channels 58, Mn-SOD 61, and 12-lipoxygenase 54.
In addition to the above molecules, the reactive oxygen species, superoxide and the
reactive nitrogen species, nitric oxide have received particular attention for their essential
role in inducing delayed anesthetic preconditioning47,50,126. Despite significant evidence
implicating ROS and RNS in the induction of delayed APC, how they exert a protective
effect is not well understood.
Superoxide-mediated oxidation of cysteines on the zinc binding proteins
metallothioneins I + II has been shown to result in the release of zinc to the cell
cytoplasm127. Recent studies in mouse lung endothelial cells have demonstrated that
metallothioneins I + II are also important targets of nitric oxide, again resulting in release
of bound zinc 123,128-130. Furthermore, it has been shown that pharmacological nitric
oxide donors are able to induce sufficient zinc release from metallothioneins to activate
metal-responsive transcription factor-1 (MTF-1), the primary transcription factor
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regulating metallothionein expression during oxidative and heavy metal stress131.
Activation of MTF-1 by increased cellular zinc causes it to translocate from the
cytoplasm to the nucleus leading to increased metallothionein production123. It has been
hypothesized that MTF-1, in conjunction with oxidative release of zinc from
metallothioneins, may participate in a novel signal transduction pathway that provides
protection against oxidative stress 131-134. Given that ROS and RNS are widely reported to
play instrumental roles in the induction of delayed preconditioning, combined with our
recent finding that metallothioneins I + II play a central role in delayed preconditioning
45

, we, in this final study, investigated a possible role for metallothioneins as sensors of

oxidative stress following preconditioning with the inhaled anesthetic isoflurane, the
reactive nitrogen species nitric oxide and the oxygen radical superoxide.

METHODS
Animal Care
129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J (MTKO, metallothionein-I + II knockout)
and 129S7/SvImJ (129, control strain for MT-I + II knockout) mice were initially
purchased from Jackson Laboratories (Bar Harbor, ME) and a breeding colony
established. Animals were kept under a standard 12:12 light:dark cycle at room
temperature and given access to food and water ad libitum. Animals were housed and all
experiments carried out with protocols approved by Smith College Institutional Animal
Care and Use Committee (Northampton, MA, USA) according to the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health, 1996).
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Primary neuronal cultures
Neonatal mouse pups postnatal day 1-3 (P1-3) were sacrificed by decapitation.
Cortices were dissected out, minced and placed in modified DMEM (80% DMEM , 10%
FBS, 10% F12 medium and 10 µg/ml Pen/Strep). Tissue was digested in dilute
Trypsin/HBSS (1:1, v/v) for 25 min, then quenched with 50% horse serum prior 3min
centrifugation to pellet tissue. The tissue was triturated then filtered through a Steriflip™
100µM nylon filter (Millipore; Billerica, MA) and plated onto poly-lysine coated tissue
culture plates. Cultures were maintained in a 5% CO2 incubator at 37˚C for 10-12 days
in vitro (DIV 10-12).

Preconditioning Regimens
Isoflurane preconditioning was accomplished using a humidified exposure
chamber containing inlet and outlet ports housed inside a 37˚ incubator. Cultures (DIV
10-12) were placed in the exposure chamber and an air/CO2 mix (95% air/5% CO2) was
passed through an Isotec 3™isoflurane vaporizer (GE Healthcare; Waukesha, WA) to
deliver 2.5% isoflurane/ 92.5% air/ 5% CO2 at a rate of 0.4 L/min for 2 hrs. In
experiments blocking iNOS and superoxide, cells were incubated with the inducible nitric
oxide synthase inhibitor, aminoguanidine (AG, 1.0 mM, Sigma) and the superoxide
dismutase mimetic manganese (III) tetrakis (4-benzoic acid) porphyrin chloride
(MnTBAP, 1.0 M, Sigma), respectively, 2 hrs prior to the anesthetic preconditioning.
Freshly made S-Nitroso-N-acetylpenicillamine (SNAP, 200µM, Sigma), degraded
SNAP (SNAP degraded at 37˚ overnight in culture media), and paraquat (5µM, Sigma)
were used for nitric oxide and superoxide preconditioning respectively. Cultures were

63

returned to the incubator for the 2 hr preconditioning period. All preconditioning
regimens were followed by 3 washes with fresh media. Cultures used for toxicity assays,
were returned to the incubator for 72 hrs until OGD (see below) in order to achieve peak
isoflurane mediated-protection, 45. Cultures being used for MTF-1 translocation
experiments were processed immediately for nuclear protein extraction 123. Each media
change performed in preconditioned cultures was performed in parallel in control
cultures.

Oxygen-Glucose Deprivation
Oxygen glucose deprivation (OGD) exposures were carried out as previously
described 40,45 with some modifications. Cell cultures were washed 4 times with zeroglucose DMEM (Gibco) and placed in a humidified anoxic chamber (model A-141,
Sheldon Mfg., Cornelius, OR) at 37˚C. The chamber was evacuated and flushed 3 times
with 90% N2, 5% H2, and 5% CO2. A palladium catalyst was maintained in the incubator
to further diminish O2 levels. Cultures were maintained in the anoxic chamber for 4 hrs
prior to LDH assay. All control cultures not receiving OGD treatment were handled in
parallel, but washes were performed with standard media rather than with OGD media.

Lactate Dehydrogenase assay for determination of cellular toxicity
Global cellular toxicity was assessed using a CytoTox™ LDH assay (Promega,
Madison WI). Briefly, following experimental treatment, 50µl media were removed
from each culture well and placed in a separate well-plate. 50 µl of LDH assay solution
was added to each well and allowed to incubate in the dark at RT for 30 min. At the end
of the incubation period, 50µl stop solution was added and color change was measured at
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490nm on a Bio-TEK µQuant™ UV/Vis plate reader (BioTEK Instruments; Winooski
VT). Net color change was determined by subtracting the average value of media-only
wells from experimental values. In order to compare results between experiments, data
were normalized to “% normalized protection” by dividing each individual experimental
value by the average control value. Thus the equation for generating normalized data
was as follows: 100-100*( AbsExperimental -AbsAverage-edia) / AbsAverage(-contro)l-AbsAverage-Media)
%.

Isolation of nuclear proteins for determination of MTF-1 translocation
Immediately following preconditioning regimen, plates were washed 3X with ice
cold PBS. Cells were then scraped with 1mL PBS on ice, placed in a microcentrifuge
tube and spun at 500 x g for 3 min to pellet the cells. The supernatant was then removed
and replaced with the outer membrane lysis buffer (0.01M Hepes, 1.5mM MgCl2, 0.01M
KCl, 1.0mM, DTT ) at ~10X packed cell volume and incubated on ice for 15 min.
Igepal-CA630 non-ionic detergent (10% v/v; Sigma) was added to the cell suspension for
a final concentration of 1%. Samples were immediately vortexed and centrifuged at
21000 x g for 5 min. Supernatant containing cytosolic proteins was removed and the
pellet containing nuclei was washed 2x in 500µL Buffer I (without Igepal). The nuclear
pellet was then resuspended in 200µl Buffer II (nuclear extraction buffer; 0.02M HEPES,
1.5mM MgCl2, 0.42 M NaCl, 200µM EDTA, 25% glycerol, 1.0mM, DTT), pipettemixed to break up pellet, and incubated on ice for 40 min. Samples were then vortexed
for 30 secs and centrifuged at 21000 x g for 15 min. Supernatant containing the nuclear
fraction was transferred to a fresh tube. Protein concentration was determined by BCA
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assay (Pierce), and samples were stored at -20 C. The nuclear pellet was observed prior
to nuclear lysis by phase-contrast and epifluorescence microscopy (with Hoeschst 33342
nuclear stain; Invitrogen) and found to contain only nuclei with little to no cellular debris
(not shown).

Western Determination of MTF-1 levels
Nuclear proteins (20µg) were separated by electrophoresis on 4-12% Bis-Tris
polyacrylamide gels (Novex, Invitrogen) and transferred to 0.45µM nitrocellulose
membrane (Invitrogen). Membranes were probed with a polyclonal antibody against
MTF-1 (1:750; Santa Cruz Bio, SC-48775) and detected with an HRP-conjugated antirabbit 2˚ antibody (1:100,000 Santa Cruz Bio, SC-2004). Bands were visualized with
Supersignal West Pico chemiluminescent Substrate (Pierce) and detected on film (Kodak
X-Omat LS, Sigma). Relative densitometry was performed in Photoshop 9.02 (Abobe
Inc., San Jose, CA) for quantitative analysis of bands from 3 replicates of each
condition135.

Statistics
All statistics were performed in SPSS 9.0 (SPSS Inc., Chicago IL). Normalized
toxicity/protection data were analyzed by ANOVA (Figures 4.1 A and 4.2 A and 4.3 A).
Significance level was p < 0.05 unless otherwise stated.
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Results
Nitric oxide and superoxide generators precondition wild type cultures and promote
nuclear translocation of MTF-1.
Growing evidence supports the role of reactive oxygen and reactive nitrogen
species as the primary initiators of preconditioning 47. In this group of experiments, we
attempted to use the nitric oxide donor SNAP, a degraded form of SNAP, and the
superoxide generator paraquat as preconditioning agents. Similar to previously
described preconditioning experiments using isoflurane as the preconditioning agent40,45,
SNAP preconditioned cultures demonstrated significant protection against OGD (37.6 ±
3.4%; n=28) compared to non-preconditioned cells in WT cultures (p < 0.001; n=28)
(Figure 4.1 A). Cells treated with the same concentration of SNAP that had been heat
degraded (37˚, 24hrs) were not significantly protected 8.3 ± 6.7 % (p = 0.4; n=14) and
were significantly less protected than the SNAP preconditioned cultures (p < 0.01; n=14).
Paraquat preconditioned cultures showed significant protection (24.2 ± 3.6%; n=14; p <
0.01) compared to untreated controls. In order to ensure that outcomes were the result of
preconditioning only, cultures were assessed for treatment-mediated toxicity by taking
media just prior to OGD treatment. SNAP, decomposed SNAP and paraquat showed
only small differences from basal control LDH levels (75.2 ± 2.6%, p= 0.18, n= 6), (65.5
± 1.1%; p < 0.05; n=6) and (82 ± 3.1%; p= 0.26, n=6) of control levels respectively.; p =
0.18 and p < 0.05 respectively; n=6) . Though the degraded SNAP value was statistically
significant, it represented a small absolute difference from the control value and were not
considered to affect the final outcome
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Reactive oxygen and nitrogen species have previously been shown to induce
nuclear translocation of MTF-1 133. We were interested to determine if the
preconditioning described above correlated with increased nuclear MTF-1 localization.
Following 2hrs on from the initiation of preconditioning, SNAP and paraquat treatments
resulted in increased nuclear MTF-1 levels (by 72 ± 21% and 231 ± 103% above
untreated control levels respectively; n=3, Figures 4.1 B and C). Degraded SNAP
showed minimal MTF-1 translocation compared to non-degraded SNAP (17 ± 4.9%
above untreated control; n=3, Figures 4.1 B and C). Together these results support a role
for MTF-1 in NO and .O2 –induced delayed protection.

Isoflurane preconditions wild type cultures and promotes nuclear translocation of
MTF-1
Given the above finding that nitric oxide and superoxide generators were able to
induce delayed preconditioning and that the protection corresponded with increased
nuclear MTF-1 localization, we determined whether a clinically relevant dose of
isoflurane would yield similar results. In agreement with earlier reports40,45,
preconditioning with a 2 hr, 2.5% isoflurane exposure provided significant levels of
protection against 4hr oxygen-glucose deprivation (29.8 ± 2.2% ; p < 0.001; n=15)
compared to non-preconditioned cultures (Figure 4.2 A). Also in agreement with
previous results17,40, the inducible nitric oxide inhibitor, aminoguanidine and the
superoxide dismutase mimetic, MnTBAP, diminished isoflurane-mediated protection to
5.8 ± 4.9 % (p = 0.47; n=18) and 6.8 ± 4.8% (p = 0.28; n=14) of control levels. Similar
to findings with pharmacologic nitric oxide and superoxide donors, Western blot analysis
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showed isoflurane treatment corresponded with increased nuclear localization of MTF-1
(55 ± 2.4% above untreated controls; n=3). Pretreatment with aminoguanidine and
MnTBAP reduced these nuclear MTF-1 levels to -6.0 ± 7.3% (n=3) and 20 ± 2.9% (n=3)
above control levels respectively (Figures 4.2 B and C). These data support a role for
MTF-1 in NO and .O2 –induced delayed protection as a result of isoflurane exposure

Knockout of MT-I + II diminishes isoflurane, nitric oxide, and superoxide-mediated
preconditioning and diminishes nuclear MTF-1 levels.
Metallothioneins I + II have been shown to play a central role in RNS/ROS
mediated translocation of MTF-1123 and we recently showed that they are important for
the induction of isoflurane-mediated delayed preconditioning 45. In these experiments,
we wanted to determine if the loss of MT-I + II genes would affect preconditioning by
SNAP and paraquat and if this would correlate with nuclear MTF-1 translocation. In
agreement with previous isoflurane preconditioning data 45, isoflurane, nitric oxide and
paraquat provided no significant protection against 4hr OGD compared to untreated
controls in metallothionein I + II knockout-derived cultures (0.92 ± 1.8%; n= 22; p =
0.81), (-1.58 ± 2.7%; n=24, p = 0.76), and (-5.6 ± 4.1%; n=14, p = 0.24) respectively
(Figure 4.3). Toxicity of the treatments alone in knockout-derived cultures was assessed
by LDH following the 72 hr preconditioning window there was no significant toxicity
from any of the treatments alone (paraquat 8 ± 4.2% above control levels ; n=8; p=0.21),
anesthetic preconditioning (12 ± 8.5% above control levels; n=8; p=0.27) and SNAP (2.0
± 3.7% below control levels; n=8; p= 0.57; n=8)
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Western analysis of nuclear MTF-1 levels in metallothionein knockout cultures
showed that nuclear MTF-1 levels were increased 3.0 ± 9.7%, 18 ± 3.0%, and 31 ± 2.7%
respectively, above controls (n=3 for each). Though preconditioning appeared to
increase nuclear MTF-1 localization, levels were sharply attenuated compared to wild
type cultures (Figure 4.3 B and C). Taken together, these data support an important role
for metallothioneins I + II both in propagating NO signaling, but also in NO and .O2
mediated protective signaling.

Discussion
Protection through delayed preconditioning has been demonstrated in variety of
tissues40-43,45,136 and animal models38,40,45,46,136 resulting in improved histological and
functional outcomes. Furthermore, the relative safety of anesthetic preconditioning
compared to ischemic preconditioning6 59, and the global nature of its protection has
contributed to growing interest in the mechanisms of APC. While many aspects of the
delayed preconditioning mechanism have been described, there are still gaps in our
understanding. Reactive nitrogen species, primarily in the form of nitric oxide
40,42,47,50,117

and reactive oxygen species such as superoxide 49,137have been shown to be

important mediators of delayed preconditioning. However, the mechanism by which
these molecules are able to confer protection is not well understood. We recently reported
that the metal-binding proteins metallothioneins I and II are important for isofluranemediated delayed preconditioning 45. In the current study, we used a dissociated neuronal
culture model to examine the hypothesis that metallothioneins I + II play a role in RNS
and ROS signaling and protection during delayed anesthetic preconditioning. Using an in
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vitro model allowed us to isolate direct pharmacologic effects of the preconditioning
agents while avoiding confounding variables such as changes in hemodynamics, cardiac
depression, and other anesthetic related physiological effects. Nevertheless, an in vitro
model has limitations. For example, it is not well suited to address system effects such as
inflammation, immune response, and drug clearance that may play an important role in
long-term outcomes of ischemic injury 11. Furthermore, in vivo models are better able to
evaluate long-term cognitive and neurological outcomes of protection and ischemia.
Despite these constraints, in vitro models have been shown by us and others to be useful
models for studying the acute effects of anesthetic preconditioning, with similar time
courses and levels of protection to in vivo models 40,45,103,138.
In this study, we determined the following: 1.) As previously reported40,45,
isoflurane preconditioning provided significant cellular protection against 4hr OGD while
the nitric oxide synthase inhibitor aminoguanidine and the superoxide scavenger
MnTBAP diminished the protective effects of isoflurane preconditioning. 2.) Isoflurane
treatment corresponded to increased nuclear localization of metal-reponsive transcription
factor-1 in wild type cultures. Pretreatment of cells with aminoguanidine or MnTBAP
diminished the effects of isoflurane preconditioning on MTF-1 nuclear localization. 3.)
Preconditioning with the nitric oxide generator, SNAP, (but not the oxidized version of
the molecule) or the superoxide generator, paraquat, was able to protect WT-derived
cultures against 4hr OGD with time courses and magnitudes of protection similar to
isoflurane preconditioning. 4.) As in isoflurane preconditioning, treatment of wild type
cultures with SNAP or paraquat induced nuclear translocation of MTF-1. 5.) Knockout
of metallothionein I + II genes abrogated the protective effects of all of the

71

preconditioning agents. 5.) Isoflurane, SNAP and paraquat treated knockout cultures
showed increased MTF-1 levels, though to a lesser extent than those seen in wild type
cultures. These data support an essential role for metallothioneins I + II both transducing
ROS and RNS signaling and protection. While we expected MTF-1 localization to drop
to control levels or below in MT knockout experiments, the discrepancy may be due to
the presence of another isoform of metallothionein, MT-III, a form found primarily in the
brain139,140. Though this molecule is typically attributed different functions from those of
MT I + II 141, its structural similarities might contribute to the regulation of MT-I + II
synthesis through MTF-1 modulation.
In combination with a number of studies on the mechanisms of nitric oxide
signaling123,128,129,131,133, our data support a role for metallothioneins I + II as sensors of
increased nitric oxide and superoxide during delayed isoflurane-mediated protection. In
Figure 4.4, we present a possible model for this pathway. The pathway begins with the
generation of nitric oxide by iNOS 40,50,142 eNOS 52,143, or a combination of the two
following the administration of the preconditioning agent. In the presence of superoxide,
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nitric oxide will react to form peroxynitrite 11. Nitric oxide alone

122,128,144

, superoxide

alone 127,145 and peroxynitrite 146 have each been shown to react with the cysteines that
make up a third of the ~60 amino acids that make up metallothioneins I + II. This
reaction triggers a confirmational change in metallothionein that results in the release of
zinc from one or both its two zinc-binding domains 146,147. Zinc then complexes with
cytoplasmically localized MTF-1, causing the metal response element-binding
transcription factor to translocate to the nucleus123,148. This translocation may rely on a
cytoplasmic interaction with hypoxia-inducible transcription factor-1 149. Once in the
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nucleus, MTF-1 binds the metal response element, inducing the production of apometallothionein I + II (aka, thionein) 85,45. Apo-metallothionein and the zinc-bound
metallothionein then have a broad range of described activities that potentially play a role
in preconditioning-mediated protection including buffering cellular zinc concentrations
150

, buffering cellular redox 151, acting extracellularly to activate cellular survival

pathways 121,152, suppressing local inflammatory response 91, modulating mitochondrial
respiration 153, modulating enzyme activity through zinc modulation 154,and protecting
mitochondria against oxidative damage 85.
This study presents evidence of an important role for metallothioneins I + II as
sensors of oxidative stress in anesthetic-mediated delayed preconditioning. Further
studies will be important to unravel the mechanisms by which metallothioneins are able
to contribute to protection against toxic ischemia.
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Figure 4.1. The nitric donor SNAP and the superoxide generator paraquat
precondition wild type cultures and induce nuclear localization of MTF-1. A.) 2hr
treatment with sublethal doses of the nitric oxide donor SNAP or the superoxide
generator paraquat provide significant protection against 4hr oxygen-glucose deprivation
72 hours following preconditioning. * Significantly different from control (p < 0.05). **
Significantly different from fresh SNAP (p < 0.05) B.) SNAP and paraquat, but not the
degraded form of SNAP induce increased nuclear localization of MTF-1. C.)
Semiquantitative analysis of nuclear MTF-1 levels from Western blots (percent above
control ± SEM, n=3).
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Figure 4.2. Isoflurane preconditioning corresponds with increased MTF-1
localization. A.) Preconditioning with isoflurane provided significant protection from
4hr oxygen glucose deprivation in wild type-derived cultures. Co-incubation with the
inducible nitric oxide inhibitor, aminoguanidine, diminished isoflurane mediated
protection to non-significant levels. The superoxide dismutase mimetic MnTBAP also
diminished isoflurane mediated protection. * Significantly different from control p <
0.05. ** Significantly different from isoflurane treatment alone (p< 0.05) B.) 2 hr
isoflurane preconditioning increased nuclear levels of the metal-responsive transcription
factor-1. Aminoguanidine and MnTBAP, abrogated isoflurane-mediated increases in
nuclear MTF-1. C.) Semi-quantitative nuclear MTF-1 levels from Western blots
(percent above or below control ± SEM, n=3).
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Figure 4.3. Metallothionein I + II knockout abrogates protection from isoflurane,
nitric oxide and superoxide preconditioning, but does not block MTF-1
translocation. A.) Cultures from MT-I + II knockouts showed no significant protection
from preconditioning with isoflurane, nitric oxide or superoxide. B.) Knockout of
metallothioneins I + II attenuated nuclear translocation of MTF-1 in isoflurane, nitric
oxide and superoxide treatment treated cultures. C.) Semi-quantitative nuclear MTF-1
levels (percent above control ± SEM, n=3) from Western blots. Wild-type data from
Figures 4.1 B and 4.2 B are included for comparison with MTKO results.
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Figure 4.4. Simplified model for nitric oxide signaling involving metallothioneins.
1.) iNOS, eNOS or both activity increases in response to isoflurane treatment
40,50,52,142,143
2.) Nitric oxide will combine with superoxide if it is present 11. 3.) Nitric
oxide122,128,144, superoxide and/or peroxynitrite146 react with metallothionein cysteines to
form sulfhydryl groups. In the process, metallothionein conformation is changed such
that it releases zinc ions146,147. 4.) Metal responsive transcription factor-1 binds with zinc
and translocates to the nucleus123,148. This process may require and interaction with
hypoxia-inducible factor 1149. 5.) Once in the nucleus, MTF-1 binds to metal response
element, triggering the transcription of metallothionein I + II genes85. 6.) APO
metallothionein (aka thionein) in the cytoplasm will bind with labile zinc to form
metallothionein and confers protection against OGD by a yet to be determined
mechanism.This process may require and interaction with hypoxia-inducible factor 1149.
5.) Once in the nucleus, MTF-1 binds to metal response element, triggering the
transcription of metallothionein I + II genes85. 6.) APO metallothionein (aka thionein) in
the cytoplasm will bind with labile zinc to form metallothionein and confers protection
against OGD by a yet to be determined mechanism.
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CHAPTER 5
FUTURE DIRECTIONS

In the course of this dissertation, I was not able to address what may end up being one of
the more interesting questions of the metallothionein/preconditioning story: What is the
mechanism by which metallothioneins are able to protect against ischemic injury? The
road to answer to this question will undoubtedly be interesting, but also challenging. It
has been ~50 years since Margoshes and Vallee isolated and Kagi and Vallee
characterized metallothioneins derived from horse kidney that had been exposed to high
levels of cadmium 155. Since that time metallothioneins have been extensively studied,
and despite thousands of studies, a definitive and comprehensive role for
metallothioneins in either normal or pathological physiology has yet to emerge 156. Yet,
as reviewed by Penkowa 85, metallothioneins have been shown to participate in a number
of processes involved with cellular protection in the brain. Major biological roles for
metallothioneins, as depicted in Figure 5.1, include modulation of inflammation, control
of cellular oxidation levels, support of tissue repair and remodeling, angiogenesis, cell
cycle and proliferation, and neuronal survival and plasticity 85. And while the above roles
are described for brain, metallothioneins I + II have also been shown to be protective in
other tissues including heart 157, liver 158, kidney 112 and intestine 159, suggesting the
possibility that preconditioning induced metallothioneins may play an important role in
the protection of other tissues.
One of the more interesting questions in regards to metallothionein-mediated
protection, especially in the brain, is the provenance of the metallothioneins that provide
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protection. While the vast majority of the literature describing metallothionein-mediated
protection focuses on intracellular metallothioneins, there is a growing literature
supporting a protective role for extracellular metallothioneins 82,85. Exogenous
metallothioneins have been shown to reduce inflammation, inhibit apoptosis, and
improve remyelination in experimental autoimune encephalomyelitis (EAE), an animal
model of multiple sclerosis 91. Furthermore, exogenous MT I + II administration was
beneficial in an experimental model of traumatic brain injury 83. The acute injuries
sustained in the core of the traumatic lesion by the MT I + II –treated and control groups
were largely the same. However, in animals treated with subcutaneous MT I + II, the
tissue surrounding the core lesion showed less oxidative stress, neurodegeneration and
apoptotic cell death in the days and weeks that followed 83. MT-I + II treatment also
improved cellular repair, with increased expression of growth factors, improved
astrogliosis, and angiogenesis 83. Furthermore, the necrotic lesion cavity showed
enhanced reorganization in MT treated subjects than in controls 83. Recent work by
Amborn et al., suggests a possible mechanism for exogenous metallothionein-mediated
protection 82. They found that extracellular metallothioneins interact with plasma
membrane megalin receptors to trigger cellular protection through a signaling pathway
that involved extracellular signal-regulated kinase, protein kinase B and c-AMP response
element binding protein 82. Finally, they found exogenous metallothioneins inhibited
apoptosis by reducing expression of the proapoptotoc B-cell leukemia/lymphoma-2
interacting member of cell death (Bim(S)) 82. In order to understand how
metallothioneins are protective in the context of delayed anesthetic preconditioning, it
will be important to determine where metallothioneins I + II are acting. If
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metallothioneins are acting intra-cellularly, then approaches to increase metallothionein
expression might prove beneficial for prevention of ischemic injury in settings where
there is a known risk. On the other hand, since exogenous xenobiotic metallothioneins
appear to be well-tolerated 160, the finding that extra-cellular metallothioneins can protect
against ischemic injury would open the door to a range of potential treatment avenues
including metallothioneins, metallothionein mimetics and so forth.
Other questions that will be interesting to pursue include, but are not limited to:
1.) How does metallothionein’s role in zinc metabolism influence cellular signaling and
protection 123,129,153,161,162? Is it metallothionein or its modulation of available zinc, or
both that determine protection 153? 2.) How do metallothionein’s antioxidant
characteristics contribute to preconditioning. Do they act to simply detoxify existing
oxidants, or do they act to inhibit the production of them in the first place 85,127? 3.) Can
exogenous metallothioneins be used to protect against ischemic injury both in vitro and in
vivo? Can synthetic MT mimetics be used to greater effect82? 4.) In the context of
preconditioning, what is the role of metallothioneins in modulating inflammatory
response 91? and 5.) What role do metallothioneins I + II play in preconditioningmediated protection of other tissues?
In the work described above, we have established an important role for
metallothioneins I + II in delayed anesthetic mediated protection against ischemic injury.
In the years to come, there is much work to be done to better understand how
metallothioneins act both on their own, and in concert with other molecules involved in
preconditioning. By improving this understanding of these processes, we hope to
contribute to improved clinical outcomes for patient subject to ischemic injury.
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Figure 5.1. Summary of the major biological roles of metallothioneins I + II. Figure
modified from Penkowa 85
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CHAPTER 6
CONCLUSION

Delayed anesthetic preconditioning is a growing field of study for protection
against ischemic injury due to its promise of a multi-pathway approach, multi-tissue
protection and the relative safety of administration. This dissertation described three
projects aimed at furthering our knowledge of the mechanisms involved in phenomenon.
In our first study, we hypothesized that, given the complexity of the ischemic
cascade, it was likely that there were molecules and pathways involved in
preconditioning that had not yet been identified. Using DNA microarray we were able to
identify genes that were differentially expressed in rat liver, kidney, and heart 90min
following a clinical exposure to the commonly used volatile anesthetic, isoflurane. Given
that preconditioning has been reported in a wide range of tissues and organisms, we were
able to combine and reduce the individual tissue lists to reflect those genes that were
differentially regulated in more than one tissue and select for genes potentially involved
in conserved endogenous protection pathways. This combined approach yielded a list of
34 genes that we subjected to a more in-depth literature review. Using this approach we
were able to identify a number of interesting genes for further study including
metallothioneins I + II, basigin, and interferon regulatory factor 1.
For the second study, I selected metallothioneins I + II for further study, two
genes that were both highly differentially regulated in multiple tissues and had literature
support for potential as protective agents. In this study we established the viability of
using primary cultures in concert with oxygen-glucose deprivation to study delayed
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anesthetic preconditioning. From these experiments it was determined that our in vitro
model displayed levels of protection and protection time-courses that were very similar to
those reported for in vivo models. Once the model was established, I was able to: 1.)
establish a time-course for metallothionein I + II expression in response to isoflurane
treatment, 2.) show that both neurons and glia are protected during delayed APC and 3.)
show that neurons were both more susceptible to oxygen-glucose deprivation toxicity and
showed greater protection from preconditioning. 4.) establish, through the use of
knockdown and knockout studies, that metallothioneins are integrally involved in
isoflurane-mediated delayed protection and 5.) demonstrate through direct transfection of
exogenous metallothionein protein that metallothioneins likely act as end effectors of
protection against ischemic injury.
Finally, in the third study, I addressed the mechanism of metallothionein action in
the context of delayed preconditioning. Dirnagl, in his 2008 review of delayed
preconditioning, categorized molecules involved in preconditioning as being sensor,
transducer, or effector molecules 91. From our investigations in the second study, it
seemed likely that metallothioneins act as effector molecules whose action is directly
involved in protection. Although the knockdown and knockout studies could arguably
support any of these roles for metallothionein, the experiment in which cells were
transfected and protected by exogenous metallothionein immediately before OGD
supports a likely role for MT I + II as an end effector. The literature however, indicated
another possible role for metallothioneins as sensors of oxidative stress 123,128,129,161,163. In
order to determine if metallothioneins I + II occupy this role in the context of delayed
preconditioning, I correlated isoflurane, nitric oxide and superoxide-mediated protection
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with the nuclear translocation of the metallothionein transcription factor MTF-1. From
these studies, I was able to determine that: 1.) blocking NO or .O2 production during APC
decreased both protection and nuclear localized MTF-1. 2.) The NO and .O2 generators
alone were sufficient to precondition mixed neuronal cultures and that this too,
corresponded with increased nuclear localization of MTF-1. 3.) Finally, knockout of
metallothionein I + II genes not only eliminated protection induced by NO and .O2 but
also diminished preconditioning-mediated increases in nuclear MTF-1 levels. Together,
these data supported a role for metallothioneins I + II in delayed preconditioning as both
sensors of oxidative stress and as end effectors of protection.
In conclusion, the three studies described above contribute to our understanding
of the mechanisms of delayed anesthetic preconditioning. These studies, along with
future experiments will lead to a better understanding of the mechanisms involved in
endogenous protection and give us clues as to how to harness these pathways to provide
improved clinical outcomes.
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